Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 40
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci

  • Chen, Hongjie
  • Fan, Shaoqi
  • Stone, Jennifer
  • Thompson, Deborah J
  • Douglas, Julie
  • Li, Shuai
  • Scott, Christopher
  • Bolla, Manjeet K
  • Wang, Qin
  • Dennis, Joe
  • Michailidou, Kyriaki
  • Li, Christopher
  • Peters, Ulrike
  • Hopper, John L
  • Southey, Melissa C
  • Nguyen-Dumont, Tu
  • Nguyen, Tuong L
  • Fasching, Peter A
  • Behrens, Annika
  • Cadby, Gemma
  • Murphy, Rachel A
  • Aronson, Kristan
  • Howell, Anthony
  • Astley, Susan
  • Couch, Fergus
  • Olson, Janet
  • Milne, Roger L
  • Giles, Graham G
  • Haiman, Christopher A
  • Maskarinec, Gertraud
  • Winham, Stacey
  • John, Esther M
  • Kurian, Allison
  • Eliassen, Heather
  • Andrulis, Irene
  • Evans, D Gareth
  • Newman, William G
  • Hall, Per
  • Czene, Kamila
  • Swerdlow, Anthony
  • Jones, Michael
  • Pollan-Santamaria, Marina
  • Fernandez-Navarro, Pablo L
  • McConnell, Daniel S
  • Kristensen, Vessela N
  • Rothstein, Joseph H
  • Wang, Pei
  • Habel, Laurel A
  • Sieh, Weiva
  • Dunning, Alison M
  • Pharoah, Paul D P
  • Easton, Douglas F
  • Gierach, Gretchen L
  • Tamimi, Rulla M
  • Vachon, Celine M
  • Lindström, Sara
Background: Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. Twin studies suggest that MD phenotypes are highly heritable. However, only a small proportion of their variance is explained by identified genetic variants. Methods: We conducted a genome-wide association study, as well as a transcriptome-wide association study (TWAS), of age- and BMI-adjusted DA, NDA, and PMD in up to 27,900 European-ancestry women from the MODE/BCAC consortia. Results: We identified 28 genome-wide significant loci for MD phenotypes, including nine novel signals (5q11.2, 5q14.1, 5q31.1, 5q33.3, 5q35.1, 7p11.2, 8q24.13, 12p11.2, 16q12.2). Further, 45% of all known breast cancer SNPs were associated with at least one MD phenotype at p < 0.05. TWAS further identified two novel genes (SHOX2 and CRISPLD2) whose genetically predicted expression was significantly associated with MD phenotypes. Conclusions: Our findings provided novel insight into the genetic background of MD phenotypes, and further demonstrated their shared genetic basis with breast cancer.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Alterations in slc4a2, slc26a7 and slc26a9 drive acid–base imbalance in gastric neuroendocrine tumors and uncover a novel mechanism for a co-occurring polyautoimmune scenario

  • Calvete, Oriol
  • Reyes, José
  • Valdés-Socin, Hernán
  • Martin, Paloma
  • Marazuela Azpiroz, Mónica
  • Barroso, Alicia
  • Escalada, Javier
  • Castells, Antoni
  • Torres Ruiz, Raúl
  • Rodríguez-Perales, Sandra
  • Currás-Freixes, María
  • Benítez, Javier
Autoimmune polyendocrine syndrome (APS) is assumed to involve an immune system malfunction and entails several autoimmune diseases co-occurring in different tissues of the same patient; however, they are orphans of its accurate diagnosis, as its genetic basis and pathogenic mechanism are not understood. Our previous studies uncovered alterations in the ATPase H+/K+ Transporting Subunit Alpha (ATP4A) proton pump that triggered an internal cell acid–base imbal-ance, offering an autoimmune scenario for atrophic gastritis and gastric neuroendocrine tumors with secondary autoimmune pathologies. Here, we propose the genetic exploration of APS involving gastric disease to understand the underlying pathogenic mechanism of the polyautoimmune scenario. The whole exome sequencing (WES) study of five autoimmune thyrogastric families uncovered different pathogenic variants in SLC4A2, SLC26A7 and SLC26A9, which cotransport to-gether with ATP4A. Exploratory in vitro studies suggested that the uncovered genes were involved in a pathogenic mechanism based on the alteration of the acid–base balance. Thus, we built a custom gene panel with 12 genes based on the suggested mechanism to evaluate a new series of 69 APS patients. In total, 64 filtered putatively damaging variants in the 12 genes of the panel were found in 54.17% of the studied patients and none of the healthy controls. Our studies reveal a constellation of solute carriers that co-express in the tissues affected with different autoimmune diseases, pro-posing a unique genetic origin for co-occurring pathologies. These results settle a new-fangled genetics-based mechanism for polyautoimmunity that explains not only gastric disease, but also thyrogastric pathology and disease co-occurrence in APS that are different from clinical incidental findings. This opens a new window leading to the prediction and diagnosis of co-occurring autoimmune diseases and clinical management of patients., This research was funded by the H2020 BRIDGES project, grant number 634935, and by the 2017 BBMRI-LPC Whole Exome Sequencing Call and Instituto de Salud Carlos III, co-funded by the European Regional Development Fund (ERDF), grant number (PI16/00440)
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

  • Lázaro García, Conxi
  • GC-HBOC Study Collaborators
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • HEBON Investigators
  • BCFR Investigators
  • ABCTB Investigators
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into the etiology of breast cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

  • Lázaro García, Conxi
  • ProCURE
  • Genetic Counseling Unit, Hereditary Cancer Program
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease(1). We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 x 10(-8) with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Brunet, Joan
  • Darder, Esther
  • Valle Domínguez, Jesús del
  • Lázaro García, Conxi
  • ENIGMA Consortium
  • GENESIS Study Collaborators
  • SWE-BRCA Group
Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2-4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Shared heritability and functional enrichment across six solid cancers

  • Jiang, Xia
  • Finucane, Hilary K.
  • Schumacher, Fredrick R.
  • Schmit, Stephanie L.
  • Tyrer, Jonathan P.
  • Han, Younghun
  • Michailidou, Kyriaki
  • Lesseur, Corina
  • Kuchenbaecker, Karoline B.
  • Dennis, Joe
  • Conti, David V.
  • Cunningham, Julie M.
  • John, Esther M.
  • Couch, Fergus J.
  • Bolla, Manjeet K.
  • Casey, Graham
  • Margolin, Sara
  • Goodman, Gary
  • Evans, D. Gareth
  • Riggan, Marjorie J.
  • Gago-Dominguez, Manuela
  • Jenkins, Mattias
  • Fostira, Florentia
  • Kaneva, Radka
  • Arnold, Susanne M.
  • Offit, Kenneth
  • Ruyck, Kim De
  • Olsson, Håkan
  • Arun, Banu K.
  • Schleutker, Johanna
  • Aronson, Kristan J.
  • Caligo, Maria A.
  • Tardón, Adonina
  • Edlund, Christopher K.
  • Ingles, Sue Ann
  • Hsu, Li
  • Rosenstein, Barry S.
  • Chenevix-Trench, Georgia
  • McKay, James D.
  • Claes, Kathleen B. M.
  • Chanock, Stephen J.
  • Nordestgaard, Børge G.
  • Park, Jong Y.
  • Kupryjanczyk, Jolanta
  • Cadoni, Gabriella
  • Neal, David E.
  • Diez, Orland
  • Ferris, Robert L.
  • Stefansson, Kari
  • Cannon-Albright, Lisa A.
  • Weinberg, Clarice R.
  • McGuffog, Lesley
  • Raskin, Leon
  • Mannermaa, Arto
  • Kibel, Adam S.
  • Neuhausen, Susan L.
  • Hulick, Peter J.
  • Shen, Hongbing
  • Wichmann, H-Erich
  • Goldberg, Mark S.
  • Greene, Mark H.
  • Maehle, Lovise
  • Yannoukakos, Drakoulis
  • Garber, Judy
  • Webb, Penelope M.
  • Weissler, Mark C.
  • Pejovic, Tanja
  • Bojesen, Stig E.
  • Toland, Amanda E.
  • Blomqvist, Carl
  • Knight, Julia A.
  • Huntsman, David G.
  • Dörk, Thilo
  • Gaudet, Mia M.
  • Hong, Yun-Chul
  • Whittemore, Alice S.
  • Torres, Diana
  • Hung, Rayjean J.
  • García-Closas, Montserrat
  • Li, Li
  • Friedman, Eitan
  • Hillemanns, Peter
  • Haugen, Aage
  • Cruz Correa, Marcia
  • Wolk, Alicja
  • Olopade, Olufunmilayo I.
  • Risch, Harvey A.
  • Terry, Kathryn L.
  • Hamdy, Freddie C.
  • Burwinkel, Barbara
  • Brauch, Hiltrud
  • Parsons, Michael T.
  • Tangen, Catherine M.
  • Travis, Ruth C.
  • Middha, Pooja
  • Terry, Mary Beth
  • Newcomb, Lisa F.
  • Nielsen, Finn C.
  • Ness, Andrew R.
  • Stanford, Janet L.
  • Kraft, Peter
  • Montagna, Marco
  • Brenton, James D.
  • Roobol, Monique J.
  • Thibodeau, Stephen N.
  • Sundfeldt, Karin
  • Hampe, Jochen
  • Lubiński, Jan
  • Tung, Nadine
  • Nevanlinna, Heli
  • Chang-Claude, Jenny
  • Stone, Jennifer
  • Swerdlow, Anthony J.
  • Brenner, Hermann
  • Wiklund, Fredrik
  • Bandera, Elisa V.
  • Siegel, Erin M.
  • Lester, Jenny
  • Le, Nhu D.
  • Taylor, Jack A.
  • Chan, Andrew T.
  • Donovan, Jenny L.
  • Landi, Maria Teresa
  • Aldrich, Melinda C.
  • White, Emily
  • Stevens, Victoria L.
  • Velez Edwards, Digna R.
  • Goodman, Marc T.
  • Easton, Douglas F.
  • Dwek, Miriam
  • Berchuck, Andrew
  • deFazio, Anna
  • Devilee, Peter
  • Heitz, Florian
  • Hopper, John L.
  • Hunter, David J.
  • Peters, Ulrike
  • Albanes, Jeroen R.
  • Singer, Christian F.
  • Woll, Penella
  • Tajara, Eloiza H.
  • Brunet, Joan
  • Christiani, David C.
  • Weitzel, Jeffrey N.
  • García-Sáenz, José A.
  • Liloglou, Triantafillos
  • Phipps, Amanda I.
  • Cybulski, Cezary
  • Li, Christopher I.
  • Lazarus, Philip
  • Sawyer, Elinor J.
  • Lane, Jacqueline M.
  • Meindl, Alfons
  • Liu, Geoffrey
  • Grankvist, Kjell
  • Peters, Wilbert H. M.
  • Goode, Ellen L.
  • Godwin, Andrew K.
  • Butzow, Ralf
  • Barkardottir, Rosa B.
  • Bien, Stephanie A.
  • Ulrich, Cornelia M.
  • Brunnström, Hans
  • Goldgar, David E.
  • Lee, Eunjung
  • Koutros, Stella
  • Setiawan, V. Wendy
  • Fletcher, Olivia
  • Moysich, Kirsten B.
  • Høgdall, Estrid
  • Gallinger, Steven
  • Lacko, Martin
  • Chen, Chu
  • Beckmann, Matthias W.
  • Elías Aguado-Barrera, Miguel
  • Barnes, Daniel R.
  • Imyanitov, Evgeny N.
  • Clements, Judith
  • Pandha, Hardev
  • Lenz, Heinz-Josef
  • MacInnis, Robert J.
  • Idos, Gregory
  • Daly, Mary B.
  • Anton-Culver, Hoda
  • Winqvist, Robert
  • Khusnutdinova, Elza
  • Muir, Kenneth
  • Diergaarde, Brenda
  • Collée, J. Margriet
  • Rossing, Mary Anne
  • Radice, Paolo
  • Bjørge, Line
  • Phelan, Catherine M.
  • Usmani, Nawaid
  • Brook, Mark N.
  • Rennert, Hedy S.
  • Lindo, Noralane M.
  • West, Catharine M. L.
  • Lam, Stephan
  • Teare, M. Dawn
  • Sandler, Dale P.
  • van Rensburg, Elizabeth J.
  • Levine, Douglas A.
  • Milne, Roger L.
  • Sorensen, Karina Dalsgaard
  • Sutphen, Rebecca
  • Miller, Austin
  • Isaacs, Claudine
  • Lesse, Davor
  • Zheng, Wei
  • Campbell, Peter T.
  • Olshan, Andrew F.
  • Modugno, Francesmary
  • Ramus, Susan J.
  • James, Paul
  • Cox, Angela
  • Caldés, Trinidad
  • Wang, Qin
  • Simard, Jacques
  • Schabath, Matthew B.
  • Pasaniuc, Bogdan
  • Carvalho, André L.
  • Lambrechts, Diether
  • Antonenkova, Natalia N.
  • Andrew, Angeline S.
  • Johansson, Mikael
  • Johansson, Mattias
  • Herrero, Rolando
  • Boccia, Stefania
  • Håkansson, Niclas
  • Kjaer, Susanne K.
  • Berndt, Sonja I.
  • Lejbkowicz, Flavio
  • Pharoah, Paul D. P.
  • Hamilton, Robert J.
  • Moreno Aguado, Víctor
  • Gruber, Stephen B.
  • Gronberg, Henrik
  • Kristensen, Vessela N.
  • Sieh, Weiva
  • Saxena, Richa
  • Bickeböller, Heike
  • Joshi, Amit D.
  • Olah, Edith
  • Zienolddiny, Shanbeh
  • Vega, Ana
  • Gayther, Simon A.
  • Campbell, Ian
  • Kühl, Tabea
  • Hall, Per
  • Rennert, Gad
  • Dunning, Alison M.
  • Czene, Kamila
  • Stintzing, Sebastian
  • Osorio, Ana
  • Hoffmeister, Michael
  • Spurdle, Amanda B.
  • Marchand, Loïc Le
  • Buchanan, Daniel D.
  • Slattery, Martha L.
  • Hamann, Ute
  • Caporaso, Neil E.
  • Kelemen, Linda E.
  • Mulligan, Anna Marie
  • Fortner, Renée T.
  • Weinstein, Stephanie
  • Penney, Kathryn L.
  • Mucci, Lorelei
  • Jakubowska, Anna
  • Nikitina-Zake, Liene
  • Loupakis, Fotios
  • Van Nieuwenhuysen, Els
  • Wu, Anna H.
  • Pashayan, Nora
  • Risch, Angela
  • Andrulis, Irene L.
  • Ganz, Patricia A.
  • Maier, Christiane
  • Wu, Xifeng
  • Khaw, Kay-Tee
  • Southey, Melissa C.
  • Townsend, Paul A.
  • Thomas, Duncan C.
  • Vachon, Celine M.
  • Eccles, Diana
  • Schmidt, Marjanka K.
  • Kote-Jarai, Zsofia
  • Campa, Daniele
  • Huyghe, Jeroen R.
  • Duell, Eric J.
  • Claessens, Frank
  • May, Taymaa
  • Houlston, Richard
  • Fasching, Peter A.
  • Kim, Jeri
  • Prokofyeva, Darya
  • Giles, Graham G.
  • Karlan, Beth Y.
  • Lindström, Sara
  • Antoniou, Antonis C.
  • Figueiredo, Jane C.
  • Kiemeney, Lambertus A. L. M.
  • Eeles, Rosalind A.
  • Kogevinas, Manolis
  • Bogdanova, Natalia V.
  • Guénel, Pascal
  • Gronwald, Jacek
  • Brennan, Paul
  • Batra, Jyotsna
  • Franceschi, Silvia
  • Lindblom, Annika
  • Amos, Christopher I.
  • Leslie, Goska
  • Thomassen, Mads
  • Haiman, Christopher A.
  • Nussbaum, Robert L.
  • Benlloch, Sara
  • Al Olama, Ali Amin
  • Pring, Miranda
  • Benitez, Javier
  • Ziogas, Argyrios
  • Cancel-Tassin, Géraldine
  • Price, Alkes L.
  • Woods, Michael
  • Tworoger, Shelley S.
  • Nathanson, Katherine L.
  • Ellberg, Carolina
  • Teixeira, Manuel R.
  • Saloustros, Emmanouil
  • Tischkowitz, Marc
  • Zorn, Kristin K.
  • Plaseska-Karanfilska, Dijana
  • Newcomb, Polly A.
Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10-8), breast and ovarian cancer (rg = 0.24, p = 7 × 10-5), breast and lung cancer (rg = 0.18, p =1.5 × 10-6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10-4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

  • Feng, Helian
  • Gusev, Alexander
  • Pasaniuc, Bogdan
  • Lázaro García, Conxi
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • GC‐HBOC Study Collaborators
  • ABCTB Investigators
  • HEBON Investigators
  • BCFR Investigators
  • OCGN Investigators
Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer subtype-specific associations have been limited. In this study, we conducted a TWAS using gene expression data from GTEx and summary statistics from the hitherto largest GWAS meta-analysis conducted for breast cancer overall, and by estrogen receptor subtypes (ER+ and ER-). We further compared associations with ER+ and ER- subtypes, using a case-only TWAS approach. We also conducted multigene conditional analyses in regions with multiple TWAS associations. Two genes, STXBP4 and HIST2H2BA, were specifically associated with ER+ but not with ER- breast cancer. We further identified 30 TWAS-significant genes associated with overall breast cancer risk, including four that were not identified in previous studies. Conditional analyses identified single independent breast-cancer gene in three of six regions harboring multiple TWAS-significant genes. Our study provides new information on breast cancer genetics and biology, particularly about genomic differences between ER+ and ER- breast cancer.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
  • ABCTB Investigators
  • GEMO Study Collaborators
  • KConFab Investigators
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PAM, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and pArg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM(-/-) patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Pujana Genestar, M. Ángel
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • KConFab Investigators
  • HEBON Investigators
  • ABCTB Investigators
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants

  • Bueno Martínez, Elena
  • Sanoguera Miralles, Lara
  • Valenzuela Palomo, Alberto
  • Lorca, Víctor
  • Gómez Sanz, Alicia
  • Carvalho, Sara
  • Allen, Jamie
  • Infante, Mar
  • Pérez Segura, Pedro
  • Lázaro García, Conxi
  • Easton, Douglas F.
  • Devilee, Peter
  • Vreeswijk, Maaike P. G.
  • Hoya, Miguel de la
  • Velasco, Eladio A.
RAD51D loss-of-function variants increase lifetime risk of breast and ovarian cancer. Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility genes. Herein, we have assessed the splicing and clinical impact of splice-site and exonic splicing enhancer (ESE) variants identified through the study of similar to 113,000 women of the BRIDGES cohort. A RAD51D minigene with exons 2-9 was constructed in splicing vector pSAD. Eleven BRIDGES splice-site variants (selected by MaxEntScan) were introduced into the minigene by site-directed mutagenesis and tested in MCF-7 cells. The 11 variants disrupted splicing, collectively generating 25 different aberrant transcripts. All variants but one produced negligible levels (<3.4%) of the full-length (FL) transcript. In addition, ESE elements of the alternative exon 3 were mapped by testing four overlapping exonic microdeletions (>= 30-bp), revealing an ESE-rich interval (c.202_235del) with critical sequences for exon 3 recognition that might have been affected by germline variants. Next, 26 BRIDGES variants and 16 artificial exon 3 single-nucleotide substitutions were also assayed. Thirty variants impaired splicing with variable amounts (0-65.1%) of the FL transcript, although only c.202G>A demonstrated a complete aberrant splicing pattern without the FL transcript. On the other hand, c.214T>C increased efficiency of exon 3 recognition, so only the FL transcript was detected (100%). In conclusion, 41 RAD51D spliceogenic variants (28 of which were from the BRIDGES cohort) were identified by minigene assays. We show that minigene-based mapping of ESEs is a powerful approach for identifying ESE hotspots and ESE-disrupting variants. Finally, we have classified nine variants as likely pathogenic according to ACMG/AMP-based guidelines, highlighting the complex relationship between splicing alterations and variant interpretation.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

  • Parsons, Michael T.
  • Tudini, Emma
  • Li, Hongyan
  • Hahnen, Eric
  • Wappenschmidt, Barbara
  • Feliubadaló i Elorza, Maria Lídia
  • Aalfs, Cora M.
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alducci, Elisa
  • Alonso Cerezo, María Concepción
  • Hauke, Jan
  • Heinrich, Tilman
  • Törngren, Therese
  • Hellebrand, Heide
  • Arnold, Norbert
  • Seggewiß, Jochen
  • Caldés, Trinidad
  • Herold, Karen N.
  • Honisch, Ellen
  • Naldi, Nadia
  • Witzel, Isabell
  • Walters, Rhiannon J.
  • Rump, Andreas
  • Horvath, Judit
  • Poplawski, Nicola K.
  • Velasco, Àngela
  • Houdayer, Claude
  • Brunet, Joan
  • Cini, Giulia
  • Hübbel, Verena
  • Iglesias, Silvia
  • Wöckel, Achim
  • Steinemann, Doris
  • Izquierdo, Angel
  • Barbieri, Elena
  • Wang Gohrke, Shan
  • James, Paul A.
  • Carnevali, Ileana
  • Torres Esquius, Sara
  • Janssen, Linda A.M.
  • Jeschke, Udo
  • Kruse, Torben A.
  • Kölbl, Alexandra
  • Ledig, Susanne
  • Cops, Elisa J.
  • Vesper, Anne Sophie
  • Kaulfuß, Silke
  • Porfirio, Berardino
  • Auber, Bernd
  • Weber, Bernhard H. F.
  • Leinert, Elena
  • Rofes, Paula
  • Bruzzone, Carla
  • Woodward, Emma R.
  • Matricardi, Laura
  • Solanes, Ares
  • Carrasco, Estela
  • Mackelenbergh, Marion T.
  • Waha, Anke
  • Nathanson, Katherine L.
  • Tucker, Katherine M.
  • Bucksch, Karolin
  • Navarro, Matilde
  • Faust, Ulrike
  • Bonanni, Bernardo
  • González, Sara
  • Nevanlinna, Heli
  • Nichols, Cassandra B.
  • Cortesi, Laura
  • Wiesmüller, Lisa
  • Niederacher, Dieter
  • Vreeswijk, Maaike P. G.
  • Caux Moncoutier, Virginie
  • Nielsen, Henriette R.
  • Giesecke, Jutta
  • Hackmann, Karl
  • Azzollini, Jacopo
  • Ong, Kai Ren
  • Pachter, Nicholas
  • Galvao, Henrique C.R.
  • Couch, Fergus J.
  • Palmero, Edenir I.
  • Guerrieri Gonzaga, Aliana
  • Cagnoli, Giulia
  • Papi, Laura
  • Asperen, Christi J.
  • Pohl Rescigno, Esther
  • Ramser, Juliane
  • Cavalli, Pietro
  • Pedersen, Inge Søkilde
  • Wagner, Sebastian A.
  • Felbor, Ute
  • Darder, Esther
  • Reis, Rui M.
  • Wieland, Kerstin
  • Gismondi, Viviana
  • Blümcke, Britta
  • Zachariae, Silke
  • Calvello, Mariarosaria
  • Stiller, Mathias
  • Bartram, Claus R.
  • Feroce, Irene
  • Stoppa-Lyonnet, Dominique
  • Keupp, Katharina
  • Hoya, Miguel
  • Lucci Cordisco, Emanuela
  • Sullivan, Kelly J.
  • Susman, Rachel
  • Zampiga, Valentina
  • Guillaud Bataille, Marine
  • Concolino, Paola
  • Sutter, Christian
  • Caliebe, Almuth
  • Gómez, Carolina
  • Tavtigian, Sean V.
  • Lewis, Alexandra L.
  • Montagna, Marco
  • Teo, Soo-Hwang
  • Teulé-Vega, Àlex
  • Debatin, Irmgard
  • Thomassen, Mads
  • Kvist, Anders
  • Gutiérrez Enríquez, Sara
  • Tibiletti, Maria Grazia
  • Meindl, Alfons
  • Fine, Miriam
  • Tischkowitz, Marc
  • Blanco, Ana
  • Toss, Angela
  • Varesco, Liliana
  • Montes, Eva
  • Garcia, Encarna B.
  • Tognazzo, Silvia
  • Caligo, Maria A.
  • Kiechle, Marion
  • Haaf, Thomas
  • Vargas Parra, Gardenía María
  • Clarke, Edward M.
  • Lim, Joanna
  • Bonache, Sandra
  • Dean, Michael
  • Michelli, Rodrigo D.
  • Gensini, Francesca
  • Gross, Eva
  • Zeder Göß, Christine
  • Gambino, Gaetana
  • Loeffler, Markus
  • Investigators, Kconfab
  • Peissel, Bernard
  • Rivera, Daniela
  • Lázaro García, Conxi
  • Nicolo, Arcangela
  • Mori, Luigi
  • Harris, Marion
  • Radice, Paolo
  • Grau Garcés, Èlia
  • Moghadasi, Setareh
  • Engel, Christoph
  • Revillion, Françoise
  • Krieger, Sophie
  • Schmutzler, Rita Katharina
  • Goldgar, David E.
  • Balmaña, Judith
  • Austin, Rachel
  • Borg, Åke
  • Salinas, Monica
  • López Fernández, Adrià
  • Spurdle, Amanda B.
  • Gehrig, Andrea
  • Capone, Gabriele L.
  • Moles Fernández, Alejandro
  • Bortesi, Beatrice
  • Grill, Sabine
  • Pérez Segura, Pedro
  • Moserle, Lidia
  • Caputo, Sandrine M.
  • Hansen, Thomas V.O.
  • Rhiem, Kerstin
  • Lattimore, Vanessa L.
  • Marabelli, Monica
  • Del Valle, Jesús
  • Lalloo, Fiona
  • Pfeifer, Katharina
  • Delnatte, Capucine
  • Toland, Amanda E.
  • Müller, Clemens R.
  • Viel, Alessandra
  • Derive, Nicolas
  • Diez, Orland
  • Sánchez de Abajo, Ana María
  • Monteiro, Alvaro N.
  • Ditsch, Nina
  • Maass, Nicolai
  • Riboli, Barbara
  • Domchek, Susan M.
  • Varon-Mateeva, Raymonda
  • Weichert, Wilko
  • Dutrannoy, Véronique
  • Eccles, Diana
  • Ehrencrona, Hans
  • Trainer, Alison H.
  • Schmidt, Gunnar
  • Enders, Ute
  • Walker, Logan C.
  • Pineda Riu, Marta
  • Evans, D. Gareth
  • Larsen, Mirjam
  • Foulkes, William D.
  • Gerdes, Anne Marie
  • Ritter, Julia
  • Farra, Chantal
  • Manoukian, Siranoush
  • Tornero, Eva
  • Schoenwiese, Ulrike
  • Germani, Aldo
  • Montalban, Gemma
  • Vega, Ana
  • Lautrup, Charlotte
  • Mundhenke, Christoph
  • Quante, Anne S.
The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

BRCA2 mis-splicing: exons 17 and 18 regulation

  • Fraile-Bethencourt, Eugenia
  • Díez-Gómez, Beatriz
  • Valenzuela-Palomo, Alberto
  • Acedo, Alberto
  • Sanz, David J.
  • Goina, Elisa
  • Buratti, Emanuele
  • Velasco, Eladio
Póster presentado a la European Human Genetics Conference, celebrada en Copenague (Dinamarca) del 27 al 30 de mayo de 2017., Mutation screening of BRCA2 identifies a large fraction of variants of uncertain clinical significance (VUS). Our goal was to investigate the impact of reported variants of BRCA2 exons 17 and 18 on splicing to assess their role in hereditary breast cancer and to identify critical regulatory elements that may constitute hotspots for spliceogenic variants. A splicing reporter minigene with BRCA2 exons 14 to-20 (MGBR2_ex14-20) was constructed in the pSAD vector. Fifty-two candidate variants were selected with splicing prediction programs, introduced in MGBR2_ex14-20 by site-directed mutagenesis and assayed in MCF-7 cells. Functional mapping by microdeletions revealed essential sequences for exon recognition on the 3' end of exon 17 and the 5' end of exon 18. Thirty out of the 52 selected variants induced anomalous splicing in minigene assays with >16 different aberrant transcripts, where exon skipping was the most common event. According to the biological indicators of pathogenicity, 18 variants could be classified as disease-causing, accounting for 28.6% of all pathogenic variants of exons 17-18 at the BRCA Share database. Aberrant splicing is especially prevalent in BRCA2 exons 17 and 18 due to the presence of active ESEs, which are recognized by splicing factor as SC35 and Tra2ß that play an important role in exon recognition. Splicing functional assays with minigenes are a valuable strategy for the interpretation of VUS of any disease-gene., Projects FIS PI13/01749 (ISCIII,Spanish Ministry of Economy and Competitivity), BIO/VA34/15 (Junta Castilla-León); EF-B is supported by a predoctoral fellowship (University of Valladolid/Banco Santander) and by a Short-Fellowship (EMBO)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Caracterización funcional de variantes candidatas de splicing en genes de susceptibilidad mediante minigenes híbridos: PALB2

  • Valenzuela-Palomo, Alberto
  • Fraile-Bethencourt, Eugenia
  • Díez-Gómez, Beatriz
  • Entrala, Carmen
  • Martínez-Delgado, Beatriz
  • Villate Bejarano, Olatz
  • Tejada, María Isabel
  • Acedo, Alberto
  • Velasco, Eladio
Póster presentado al I Congreso Interdisciplinar en Genética Humana, celebrado en Madrid del 25 al 28 de abril de 2017., [Objetivos]: Los minigenes son herramientas biotecnológicas avanzadas que permiten el análisis de variantes de splicing sin necesidad de una muestra de ARN del paciente. El rastreo de genes de susceptibilidad genera una gran cantidad de variantes de significado clínico incierto que requieren una interpretación clínica. PALB2 es un gen supresor de tumores que participa en el mantenimiento de la integridad del genoma, estando implicado en la susceptibilidad hereditaria a cáncer de mama. Con el objetivo de analizar funcionalmente PALB2 desde la perspectiva del splicing, se construyó un minigen (MGPB2_5-7) dentro del proyecto europeo BRIDGES. [Material y Método]: El MGPB2_5-7 fue construido en el vector de splicing pMAD® mediante enzimas de restricción en dos pasos: exones 5-6 + exón 7. Éste se transfectó en células MCF7, se extrajo el RNA y se realizó RT-PCR específica del minigen. Los resultados fueron analizados mediante gel de agarosa, electroforesis capilar y secuenciación SANGER. [Resultados]: El minigen PB2_5-7, de 6705pb esta constituido por el vector pMAD9 (4500pb) +[ivs4(274pb)- ex5(830pb)-ivs5(364pb)-ex6(72pb)-ivs6(232pb)//ivs6(191pb)-ex7(162pb)-ivs7(114pb)]. MGPB2_5-6 dio lugar al transcrito canónico (1083nt) y 2 alternativos no caracterizados, mientras que MGPB2_5-7 indujo un transcrito estable (1245nt), estando por tanto preparado para el estudio de mutaciones de splicing. Por otro lado, a través del servicio externo del CSIC (http://www.ibgm.med.uva.es/servicios/servicio-de-splicing-minigenes/) construimos minigenes para el estudio funcional de mutaciones de splicing de los genes MLH1(Síndrome de Lynch, LorgenGP), SERPINA1(Déficit en α1-antitripsina, ISCIII), COL1A1 (Osteogénesis Imperfecta) y CHD7 (Discapacidad Intelectual Hospital Universitario Cruces). Todos ellos generaron el transcrito canónico, y se caracterizó el impacto de mutaciones de los sitios naturales de splicing. [Conclusión]: EL minigen PB2ex5-7 y las futuras ampliaciones de Este, nos permitiran realizar el análisis funcional de mutaciones de splicing, recogidas en la base de datos UMD como VUS. Los minigenes son una herramienta robusta que nos permite analizar funcionalmente el efecto en el procesamiento del ARNm que pueden causar ciertas mutaciones., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634935. EAV lab was also supported by grant Fis: PI13/01749 from the Spanish Ministry of Economy and Competitivity, Plan Nacional de I+D+I 2013-2016, ISCIII, co-funded by FEDER from Regional Development European Funds (European Union), and grant CSI090U14 (ORDEN EDU/122/2014) from the Consejería de Educación (Junta de Castilla y León, Spain)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

  • Fachal, Laura
  • Aschard, Hugues
  • Beesley, Jonathan
  • Barnes, Daniel R.
  • Allen, Jamie
  • Kar, Siddhartha
  • Pooley, Karen A.
  • Dennis, Joe
  • Michailidou, Kyriaki
  • Turman, Constance
  • Soucy, Penny
  • Lemaçon, Audrey
  • Lush, Michael
  • Tyrer, Jonathan P.
  • Ghoussaini, Maya
  • Moradi Marjaneh, Mahdi
  • Jiang, Xia
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alonso, M. Rosario
  • Andrulis, Irene L.
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arason, Adalgeir
  • Arndt, Volker
  • Aronson, Kristan J.
  • Arun, Banu K.
  • Auber, Bernd
  • Auer, Paul L.
  • Azzollini, Jacopo
  • Balmaña, Judith
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel
  • Beeghly-Fadiel, Alicia
  • Benitez, Javier
  • Bermisheva, Marina
  • Białkowska, Katarzyna
  • Blanco, Amie M.
  • Blomqvist, Carl
  • Blot, William
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bolla, Manjeet K.
  • Bonanni, Bernardo
  • Borg, Ake
  • Bosse, Kristin
  • Brauch, Hiltrud
  • Brenner, H.
  • Briceno, I.
  • Caldés, T.
  • Castelao, J. E.
  • Hoya, Miguel de la
  • Diez, Orland
  • Durán, Mercedes
  • Gago-Dominguez, Manuela
  • García-Saenz, José Ángel
  • González-Neira, Anna
  • Moreno, Fernando
  • Muñoz-Garzón, Víctor M.
  • Osorio, Ana
  • Pujana, Miguel Ángel
  • Romero, Atocha
  • Sánchez-Herrero, Estela
  • Santamariña, Marta
  • Teulé, Alex
  • Vega, Ana I.
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis with in silico genomic feature annotations. We defined 205 independent risk-associated signals with the set of credible causal variants in each one. In parallel, we used a Bayesian approach (PAINTOR) that combines genetic association, linkage disequilibrium and enriched genomic features to determine variants with high posterior probabilities of being causal. Potentially causal variants were significantly over-represented in active gene regulatory regions and transcription factor binding sites. We applied our INQUSIT pipeline for prioritizing genes as targets of those potentially causal variants, using gene expression (expression quantitative trait loci), chromatin interaction and functional annotations. Known cancer drivers, transcription factors and genes in the developmental, apoptosis, immune system and DNA integrity checkpoint gene ontology pathways were over-represented among the highest-confidence target genes., This work was supported by the European Union’s Horizon 2020 Research and Innovation Programme under Marie Sklodowska-Curie grant agreement number 656144. Genotyping of the OncoArray was principally funded from three sources: the PERSPECTIVE project (funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie de la Science et de l’Innovation du Québec’ (through Genome Québec) and the Quebec Breast Cancer Foundation); the NCI Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative and the Discovery, Biology and Risk of Inherited Variants in Breast Cancer (DRIVE) project (NIH grants U19 CA148065 and X01HG007492); and Cancer Research UK (C1287/A10118, C8197/A16565 and C1287/A16563). BCAC is funded by Cancer Research UK (C1287/A16563), by the European Community’s Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175) (COGS) and by the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements 633784 (B-CAST) and 634935 (BRIDGES). Genotyping of the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710), the Canadian Institutes of Health Research for the ‘CIHR Team in Familial Risks of Breast Cancer’ program, and the Ministry of Economic Development, Innovation and Export Trade of Quebec (grant PSR-SIIRI-701). Combining of the GWAS data was supported in part by NIH Cancer Post-Cancer GWAS initiative grant U19 CA 148065 (DRIVE; part of the GAME-ON initiative).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comprehensive Functional Characterization and Clinical Interpretation of 20 Splice-Site Variants of the RAD51C Gene

  • Sanoguera-Miralles, Lara
  • Valenzuela-Palomo, Alberto
  • Bueno-Martínez, Elena
  • Llovet, Patricia
  • Díez-Gómez, Beatriz
  • Caloca, María J.
  • Pérez-Segura, Pedro
  • Fraile-Bethencourt, Eugenia
  • Colmena, Marta
  • Carvalho, Sara
  • Allen, Jamie
  • Easton, Douglas F.
  • Devilee, Peter
  • Vreeswijk, Maaike P. G.
  • Hoya, Miguel de la
  • Velasco, Eladio
© 2020 by the authors., Hereditary breast and/or ovarian cancer is a highly heterogeneous disease with more than 10 known disease-associated genes. In the framework of the BRIDGES project (Breast Cancer Risk after Diagnostic Gene Sequencing), the RAD51C gene has been sequenced in 60,466 breast cancer patients and 53,461 controls. We aimed at functionally characterizing all the identified genetic variants that are predicted to disrupt the splicing process. Forty RAD51C variants of the intron-exon boundaries were bioinformatically analyzed, 20 of which were selected for splicing functional assays. To test them, a splicing reporter minigene with exons 2 to 8 was designed and constructed. This minigene generated a full-length transcript of the expected size (1062 nucleotides), sequence, and structure (Vector exon V1- RAD51C exons_2-8- Vector exon V2). The 20 candidate variants were genetically engineered into the wild type minigene and functionally assayed in MCF-7 cells. Nineteen variants (95%) impaired splicing, while 18 of them produced severe splicing anomalies. At least 35 transcripts were generated by the mutant minigenes: 16 protein-truncating, 6 in-frame, and 13 minor uncharacterized isoforms. According to ACMG/AMP-based standards, 15 variants could be classified as pathogenic or likely pathogenic variants: c.404G > A, c.405-6T > A, c.571 + 4A > G, c.571 + 5G > A, c.572-1G > T, c.705G > T, c.706-2A > C, c.706-2A > G, c.837 + 2T > C, c.905-3C > G, c.905-2A > C, c.905-2_905-1del, c.965 + 5G > A, c.1026 + 5_1026 + 7del, and c.1026 + 5G > T., PD: MPGV: DFE: MdlH and EAV have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634935. EAV lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I + D+I 2013–2016, ISCIII (PI17/00227) co-funded by FEDER from Regional Development European Funds (European Union) and from the Consejería de Educación, Junta de Castilla y León, ref. CSI242P18 (actuación cofinanciada P.O. FEDER 2014–2020 de Castilla y León). MdlH is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I + D+I 2013–2016, ISCIII (PI15/00059) co-funded by FEDER from Regional Development European Funds (European Union).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Splicing Functional Assays of splice-site variants of the breast cancer gene PALB2 identified in the BRIDGES project

  • Valenzuela-Palomo, Alberto
  • Bueno-Martínez, Elena
  • Sanoguera-Miralles, Lara
  • Velasco, Eladio
Splicing and genetic susceptibility to cancer, Instituto de Biología y Genética Molecular. Consejo Superior de Investigaciones Científicas (CSIC-UVa), 47003 Valladolid, Spain., This dataset corresponds to a systematic splicing analysis of PALB2 splice-site variants that had been detected in over 113,000 women who took part of the large scale sequencing project BRIDGES. Eighty-two variants of the intron-exon boundaries were bioinformatically analyzed, and 42 of them were selected for subsequent splicing assays in three minigene constructs. Thirty-five variants impaired splicing, 23 of which were classified as pathogenic/likely pathogenic variants according to ACMG/AMP-based guidelines, so that carrier patients and families may benefit from tailored prevention protocols and personalized therapies., Eladio A. Velasco (EAV) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634935. EAV lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI17/00227 and PI20/00225) co-funded by FEDER from Regional Development European Funds (European Union) and from the Consejería de Educación, Junta de Castilla y León, ref. CSI242P18 (actuación cofinanciada P.O. FEDER 2014-2020 de Castilla y León). Alberto Valenzuela-Palomo is supported by a predoctoral fellowship from the Consejería de Educación, Junta de Castilla y León (2018–2022). Lara Sanoguera-Miralles is supported by a predoctoral fellowship from the AECC-Scientific Foundation, Sede Provincial de Valladolid (2019–2023)., Transcript Sequencing. Folders: cdna.mgpb2_5-12, cdna.mgpb2_ex1-3, cdnamgpb2_ex4-6.-- Fluorescent Fragment Analysis. Folders: FAM_mgpb2_ex1-3, FAMmgpb2_4-6, FAMmgpb2_ex5-12.-- Minigene Sequencing. Folders: MINIGEN mgpb2_1-3, MINIGEN mgpb2_4-6, MINIGEN mgpb2_5-12, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants

  • Bueno-Martínez, Elena
  • Sanoguera-Miralles, Lara
  • Valenzuela-Palomo, Alberto
  • Lorca, Víctor
  • Gómez-Sanz, Alicia
  • Carvalho, Sara
  • Allen, Jamie
  • Infante, Mar
  • Pérez-Segura, Pedro
  • Lázaro, Conxi
  • Easton, Douglas F.
  • Devilee, Peter
  • Vreeswijk, Maaike P. G.
  • Hoya, Miguel de la
  • Velasco, Eladio
© 2021 by the authors., RAD51D loss-of-function variants increase lifetime risk of breast and ovarian cancer. Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility genes. Herein, we have assessed the splicing and clinical impact of splice-site and exonic splicing enhancer (ESE) variants identified through the study of ~113,000 women of the BRIDGES cohort. A RAD51D minigene with exons 2–9 was constructed in splicing vector pSAD. Eleven BRIDGES splice-site variants (selected by MaxEntScan) were introduced into the minigene by site-directed mutagenesis and tested in MCF-7 cells. The 11 variants disrupted splicing, collectively generating 25 different aberrant transcripts. All variants but one produced negligible levels (<3.4%) of the full-length (FL) transcript. In addition, ESE elements of the alternative exon 3 were mapped by testing four overlapping exonic microdeletions (≥30-bp), revealing an ESE-rich interval (c.202_235del) with critical sequences for exon 3 recognition that might have been affected by germline variants. Next, 26 BRIDGES variants and 16 artificial exon 3 single-nucleotide substitutions were also assayed. Thirty variants impaired splicing with variable amounts (0–65.1%) of the FL transcript, although only c.202G>A demonstrated a complete aberrant splicing pattern without the FL transcript. On the other hand, c.214T>C increased efficiency of exon 3 recognition, so only the FL transcript was detected (100%). In conclusion, 41 RAD51D spliceogenic variants (28 of which were from the BRIDGES cohort) were identified by minigene assays. We show that minigene-based mapping of ESEs is a powerful approach for identifying ESE hotspots and ESE-disrupting variants. Finally, we have classified nine variants as likely pathogenic according to ACMG/AMP-based guidelines, highlighting the complex relationship between splicing alterations and variant interpretation., P.D., M.P.G.V., D.F.E., M.d.l.H. and E.A.V. have received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 634935. E.A.V.’s lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I + D + I 2013–2016, ISCIII (PI17/00227 and PI20/00225), co-funded by FEDER from Regional Development European Funds (European Union) and from the Consejería de Educación, Junta de Castilla y León, ref. CSI242P18 (actuación cofinanciada P.O. FEDER 2014–2020 de Castilla y León). M.d.l.H.’s lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I + D + I 2013–2016, ISCIII (PI15/00059 and PI20/00110) and co-funded by FEDER from Regional Development European Funds (European Union). L.S.-M. is supported by a predoctoral fellowship from the AECC-Scientific Foundation, Sede Provincial de Valladolid (2019–2023). A.V.-P. is supported by a predoctoral fellowship from the Consejería de Educación, Junta de Castilla y León (2018–2022). Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Escalera de Excelencia, Junta de Castilla y León (Ref. CLU-2019-02).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Splicing Functional Assays of ATM splice-site variants identified in the BRIDGES project

  • Bueno-Martínez, Elena
  • Valenzuela-Palomo, Alberto
  • Sanoguera-Miralles, Lara
  • Velasco, Eladio
[Description of methods used for collection/generation of data] Splicing functional assays of ATM variants by hybrid minigenes, [Instrument- or software-specific information needed to interpret/reproduce the data] - Sequence analysis (.ab1 files) with appropriate software, such as SnapGene Viewer (https://www.snapgene.com/snapgene-viewer/). - Fluorescent Fragment analysis (.fsa files) with Peak Scanner v1.0 (https://www.thermofisher.com/order/catalog/product/4381867#/4381867)., [Standards and calibration information] Fragment analysis electrophoresis was run with Liz1200 as size standard., [Environmental/experimental conditions] As indicated in the submitted manuscript., [People involved with sample collection, processing, analysis and/or submission] Bueno-Martínez, Elena (E.B.-M); Valenzuela-Palomo, Alberto (A.V.-P.); Sanoguera-Miralles, Lara (L.S.-M.); Velasco Sampedro, Eladio A (E.A.V.-S.) Conceptualization, E.A.V.-S.; Data curation, E.B.-M., L.S.-M., A.V.-P.; Formal analysis, E.B.-M., L.S.-M., A.V.-P. and E.A.V.-S.; Funding acquisition, E.A.V.-S.; Investigation, E.B.-M., L.S.-M., A.V.-P. and E.A.V.-S.; Methodology, A.V.-P., L.S.-M., E.B.-M., A.G.-A., and E.A.V.-S.; Supervision, E.A.V.-S., Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). This only allows people to download and share your work for no commercial gain and for no other purposes., This dataset corresponds to a systematic splicing analysis of splice-site variants of the breast cancer susceptibility gene ATM, which had been sequenced in 113,000 women who took part of the large-scale sequencing project BRIDGES. A set of 381 variants at the intron-exon boundaries were identified, 128 of which were predicted spliceogenic. After further filtering, we ended up selecting 56 variants for splicing analysis in four minigene constructs. Forty-eight variants impaired splicing, 29 of which were classified as pathogenic/likely pathogenic variants according to ACMG/AMP-based guidelines, so that carrier patients and families may benefit from tailored prevention protocols and personalized therapies., Eladio A. Velasco (EAV) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634935. EAV lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI17/00227 and PI20/00225) co-funded by FEDER from Regional Development European Funds (European Union) and from the Consejería de Educación, Junta de Castilla y León, ref. CSI242P18 (actuación cofinanciada P.O. FEDER 2014-2020 de Castilla y León). Elena Bueno-Martínez is a postdoctoral researcher funded by the University of Valladolid (POSTDOC-UVA05, 2022-2025).Alberto Valenzuela-Palomo is supported by a predoctoral fellowship from the Consejería de Educación, Junta de Castilla y León (2018–2022). Lara Sanoguera-Miralles is supported by a predoctoral fellowship from the AECC-Scientific Foundation, Sede Provincial de Valladolid (2019–2023)., Folder: cDNA_SEQUENCES. Transcript Sequencing. Sub-Folders: • Sequences_ATM 4-9 • Sequences_ATM 11-17 • Sequences_ATM 17-22 • Sequences_ATM 25-29 • Sequences_ATM 49-52 Folder: FRAGMENT_ANALYSIS. Fluorescent Fragment Analysis. Sub-Folders: • Fragment_Analysis_ATM 4-9 • Fragment_Analysis_ATM 11-17 • Fragment_Analysis_ATM 25-29 • Fragment_Analysis_ATM 49-52, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants

  • Bueno-Martínez, Elena
  • Sanoguera-Miralles, Lara
  • Valenzuela-Palomo, Alberto
  • Esteban-Sánchez, Ada
  • Lorca, Víctor
  • Llinares-Burguet, Inés
  • Allen, Jamie
  • García-Álvarez, Alicia
  • Pérez-Segura, Pedro
  • Durán, Mercedes
  • Easton, Douglas F.
  • Devilee, Peter
  • Vreeswijk, Maaike P. G.
  • Hoya, Miguel de la
  • Velasco, Eladio
The ataxia telangiectasia-mutated (ATM) protein is a major coordinator of the DNA damage response pathway. ATM loss-of-function variants are associated with 2-fold increased breast cancer risk. We aimed at identifying and classifying spliceogenic ATM variants detected in subjects of the large-scale sequencing project BRIDGES. A total of 381 variants at the intron-exon boundaries were identified, 128 of which were predicted to be spliceogenic. After further filtering, we ended up selecting 56 variants for splicing analysis. Four functional minigenes (mgATM) spanning exons 4-9, 11-17, 25-29, and 49-52 were constructed in the splicing plasmid pSAD. Selected variants were genetically engineered into the four constructs and assayed in MCF-7/HeLa cells. Forty-eight variants (85.7%) impaired splicing, 32 of which did not show any trace of the full-length (FL) transcript. A total of 43 transcripts were identified where the most prevalent event was exon/multi-exon skipping. Twenty-seven transcripts were predicted to truncate the ATM protein. A tentative ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based classification scheme that integrates mgATM data allowed us to classify 29 ATM variants as pathogenic/likely pathogenic and seven variants as likely benign. Interestingly, the likely pathogenic variant c.1898+2T>G generated 13% of the minigene FL-transcript due to the use of a noncanonical GG-5'-splice-site (0.014% of human donor sites). Circumstantial evidence in three ATM variants (leakiness uncovered by our mgATM analysis together with clinical data) provides some support for a dosage-sensitive expression model in which variants producing ¿30% of FL-transcripts would be predicted benign, while variants producing ¿13% of FL-transcripts might be pathogenic., PD, MPGV, DFE, MdlH and EAV received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 634935. The EAV lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI17/00227 and PI20/00225) co-funded by the FEDER from Regional Development European Funds (European Union) and from the Consejería de Educación, Junta de Castilla y León, ref. CSI242P18 (actuación cofinanciada P.O. FEDER 2014-2020 de Castilla y León). The MdlH lab is supported by a grant from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI20/00110) co-funded by FEDER from Regional Development European Funds (European Union). Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Escalera de Excelencia, Junta de Castilla y León (Ref. CLU-2019-2002). EB-M is a postdoctoral researcher funded by the University of Valladolid (POSTDOC-UVA05, 2022-2025). AV-P and IL-B are supported by predoctoral fellowships from the Consejería de Educación, Junta de Castilla y León. LS-M is supported by a predoctoral fellowship from the AECC-Scientific Foundation, Sede Provincial de Valladolid (2019–2023). AE-S is supported through the Operational Program for Youth Employment and Youth Employment Initiative (YEI), called by the Community of Madrid in 2020, and co-financed by the European Social Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Splicing predictions, minigene analyses and ACMG/AMP clinical classification of 42 germline PALB2 splice-site variants

  • Valenzuela-Palomo, Alberto
  • Bueno-Martínez, Elena
  • Sanoguera-Miralles, Lara
  • Lorca, Víctor
  • Fraile-Bethencourt, Eugenia
  • Esteban-Sánchez, Ada
  • Gómez-Barrero, Susana
  • Carvalho, Sara
  • Allen, Jamie
  • García-Álvarez, Alicia
  • Pérez-Segura, Pedro
  • Dorling, Leila
  • Easton, Douglas F.
  • Devilee, Peter
  • Vreeswijk, Maaike P. G.
  • Hoya, Miguel de la
  • Velasco, Eladio
PALB2 loss-of-function variants confer high risk of developing breast cancer. Here, we present a systematic functional analysis of PALB2 splice-site variants detected in ~113,000 women of the large-scale sequencing project BRIDGES (Breast Cancer After Diagnostic Gene Sequencing; https://bridges-research.eu/). Eighty-two PALB2 variants at the intron-exon boundaries were analyzed with MaxEntScan. Forty-two variants were selected for the subsequent splicing functional assays. For this purpose, three splicing reporter minigenes comprising exons 1-12 were constructed. The 42 potential spliceogenic variants were introduced into the minigenes by site-directed mutagenesis and assayed in MCF-7/MDA-MB-231 cells. Splicing anomalies were observed in 35 variants, 23 of which showed no traces or minimal amounts of the expected full-length transcripts of each minigene. More than 30 different variant-induced transcripts were characterized, 23 of which were predicted to truncate the PALB2 protein. The pathogenicity of all variants was interpreted according to an in-house adaptation of the ACMG/AMP (American College of Medical Genetics and Genomics and the Association for Molecular Pathology) variant classification scheme. Up to 23 variants were classified as Pathogenic/Likely Pathogenic. Remarkably, three ±1,2 variants (c.49-2A>T, c.108+2T>C and c.211+1G>A) were classified as variants of unknown significance since they produced significant amounts of either in-frame transcripts of unknown impact on the PALB2 protein function or the minigene full-length transcripts. In conclusion, we have significantly contributed to the ongoing effort of identifying spliceogenic variants in the clinically relevant PALB2 cancer susceptibility gene. Moreover, we suggest some approaches to classify the findings in accordance with the ACMG/AMP rationale., PD, MPGV, DFE, MdlH, and EAV have received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 634935. The laboratory of EAV is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI17/00227 and PI20/00225) co-funded by FEDER from Regional Development European Funds (European Union) and from the Consejería de Educacion, Junta de Castilla y Leon, ref. CSI242P18 (actuacion cofinanciada P.O. FEDER 2014-2020 de Castilla y Leon). The laboratory of MdlH is supported by a grant from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI20/00110) co-funded by FEDER from Regional Development European Funds (European Union). Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Escalera de Excelencia, Junta de Castilla y León (ref. CLU-2019-02). AV-P is supported by a predoctoral fellowship from the Consejería de Educación, Junta de Castilla y León (2018–2022). LS-M is supported by a predoctoral fellowship from the AECC-Scientific Foundation, Sede Provincial de Valladolid (2019–2023). AE-S is supported through the Operational Program for Youth Employment and Youth Employment Initiative (YEI), called by the Community of Madrid in 2020, and co-financed by the European Social Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Splicing Functional Assays of CHEK2 splice-site variants identified in the BRIDGES project

  • Sanoguera-Miralles, Lara
  • Bueno-Martínez, Elena
  • Valenzuela-Palomo, Alberto
  • Velasco, Eladio
This dataset corresponds to a comprehensive study of splice-site variants of the breast cancer susceptibility gene CHEK2. Variant data have been obtained from the large-scale sequencing project BRIDGES that sequenced 34 genes in 113,000 women. A set of 128 CHEK2 variants at the intron-exon boundaries were identified, 52 of which were predicted spliceogenic. These were introduced into the three minigene constructs by site-directed mutagenesis and tested in MCF-7 cells. Forty-six variants impaired splicing, 26 of which were classified as pathogenic/likely pathogenic variants according to ACMG/AMP-based guidelines, so carrier patients and families may benefit from tailored prevention protocols and personalized therapies., Eladio A. Velasco (EAV) has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634935. EAV lab is supported by grants from the Spanish Ministry of Science and Innovation, Plan Nacional de I+D+I 2013-2016, ISCIII (PI17/00227 and PI20/00225) co-funded by FEDER from Regional Development European Funds (European Union) and from the Consejería de Educación, Junta de Castilla y León, ref. CSI242P18 (actuación cofinanciada P.O. FEDER 2014-2020 de Castilla y León). Lara Sanoguera-Miralles is supported by a predoctoral fellowship from the AECC-Scientific Foundation, Sede Provincial de Valladolid (2019–2023). Elena Bueno-Martínez is a postdoctoral researcher funded by the University of Valladolid (POSTDOC-UVA05, 2022-2025)., Folder: cDNA_Sequences. Transcript Sequencing. Sub-Folders: cDNA microdeletions CHEK2 1-7 c.684-2G; cDNA_minigenes CHEK2 1-7; cDNA_minigenes CHEK2 6-10; cDNA_minigenes CHEK2 6-14 WT y mutantes; cDNA_minigenes CHEK2 11-15; cDNA_minigenes WT.-- Folder: Fragment_Analysis. Fluorescent Fragment Analysis. Sub-Folders: Fragment_Analysis_microdeletions CHEK2 1-7 c.684-2G; Fragment_Analysis_minigenes CHEK2 1-7; Fragment_Analysis_minigenes CHEK2 6-10; Fragment_Analysis_minigenes CHEK2 6-14 y mutantes; Fragment_Analysis_minigenes CHEK2 11-15; Fragment_Analysis_minigenes WT.-- Folder: Minigenes_Sequences. Sequence files of wild type and mutant constructs. Sub-folders: Microdeletions_CHEK2 1-7-c.684-2G; Minigene_CHEK2 1-7; Minigene_CHEK2 6-10; Minigene_CHEK2 6-14 WT y mutant; Minigene_CHEK2 11-15; minigene_WT., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

Splice-site variants of the breast cancer susceptibility gene ATM. BRIDGES_Project-2

  • Llinares-Burguet, Inés
  • Velasco, Eladio
Folder: 1.Sequences - Sub-folder cDNA. Transcript Sequencing. Sub-folders: - ATM_19-22: 31 *.ab1 files of transcripts generated by variants introduced into minigene mgATM_19-22 - ATM_41-44: 15 *.ab1 files of transcripts generated by variants introduced into minigene mgATM_41-44 - ATM_55-63: 32 *.ab1 files of transcripts generated by variants introduced into minigene mgATM_55-63 - Sub-folder: Minigenes. Sequence files of wild type and mutant constructs. Sub-folders: - ATM_19-22: 17 *.ab1 files. - ATM_41-44: 11 *.ab1 files. - ATM_55-63: 25 *.ab1 files. • Folder: 2.Fragment_Analysis. Fluorescent Fragment Analysis of splicing assays. Sub-folders: - ATM_19-22: 53 *.fsa files of fluorescent fragment analysis of variant-spicing assays. - ATM_41-44: 30 *.fsa files of fluorescent fragment analysis of variant-spicing assays. - ATM_55-63: 72 *.fsa files of fluorescent fragment analysis of variant-spicing assays., This dataset contains fragment analysis and sequencing files of the impact on splicing of splice-site variants in 17 exons of the breast cancer susceptibility gene ATM. Splicing dysregulation is a well-established mechanism of pathogenicity for variants in disease susceptibility genes. Pathogenic germline variants in ATM are associated with a 20–30% lifetime risk of breast cancer. We aimed to carry out splicing analysis of ATM splice-site variants detected in subjects of the large-scale sequencing project BRIDGES (https://cordis.europa.eu/project/id/634935) by minigene assays. To this end, we bioinformatically selected 47 splice-site variants in 17 exons that were genetically engineered into three minigenes and assayed in MCF-7 cells. Aberrant splicing was observed in 38 variants. Of these, 29 showed no or negligible minigene full-length (mgFL) transcript expression, including eight exonic variants (7 missense and one nonsense). All minigene read-outs from variants were interpreted according to the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based specifications for the ATM gene., EAV-S lab has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634935, and from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (PI23/00047) co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

  • Brunet, Joan
  • Darder, Esther
  • Valle Domínguez, Jesús del
  • Lázaro García, Conxi
  • ENIGMA Consortium
  • GENESIS Study Collaborators
  • SWE-BRCA Group
Germline protein truncating variants (PTVs) in the FANCM gene have been associated with a 2-4-fold increased breast cancer risk in case-control studies conducted in different European populations. However, the distribution and the frequency of FANCM PTVs in Europe have never been investigated. In the present study, we collected the data of 114 European female breast cancer cases with FANCM PTVs ascertained in 20 centers from 13 European countries. We identified 27 different FANCM PTVs. The p.Gln1701* PTV is the most common PTV in Northern Europe with a maximum frequency in Finland and a lower relative frequency in Southern Europe. On the contrary, p.Arg1931* seems to be the most common PTV in Southern Europe. We also showed that p.Arg658*, the third most common PTV, is more frequent in Central Europe, and p.Gln498Thrfs*7 is probably a founder variant from Lithuania. Of the 23 rare or unique FANCM PTVs, 15 have not been previously reported. We provide here the initial spectrum of FANCM PTVs in European breast cancer cases.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella
  • Lázaro García, Conxi
  • Pujana Genestar, M. Ángel
  • ABCTB Investigators
  • GEMO Study Collaborators
  • KConFab Investigators
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PAM, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and pArg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM(-/-) patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status

  • Feng, Helian
  • Gusev, Alexander
  • Pasaniuc, Bogdan
  • Lázaro García, Conxi
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • GC‐HBOC Study Collaborators
  • ABCTB Investigators
  • HEBON Investigators
  • BCFR Investigators
  • OCGN Investigators
Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer subtype-specific associations have been limited. In this study, we conducted a TWAS using gene expression data from GTEx and summary statistics from the hitherto largest GWAS meta-analysis conducted for breast cancer overall, and by estrogen receptor subtypes (ER+ and ER-). We further compared associations with ER+ and ER- subtypes, using a case-only TWAS approach. We also conducted multigene conditional analyses in regions with multiple TWAS associations. Two genes, STXBP4 and HIST2H2BA, were specifically associated with ER+ but not with ER- breast cancer. We further identified 30 TWAS-significant genes associated with overall breast cancer risk, including four that were not identified in previous studies. Conditional analyses identified single independent breast-cancer gene in three of six regions harboring multiple TWAS-significant genes. Our study provides new information on breast cancer genetics and biology, particularly about genomic differences between ER+ and ER- breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants

  • Bueno Martínez, Elena
  • Sanoguera Miralles, Lara
  • Valenzuela Palomo, Alberto
  • Lorca, Víctor
  • Gómez Sanz, Alicia
  • Carvalho, Sara
  • Allen, Jamie
  • Infante, Mar
  • Pérez Segura, Pedro
  • Lázaro García, Conxi
  • Easton, Douglas F.
  • Devilee, Peter
  • Vreeswijk, Maaike P. G.
  • Hoya, Miguel de la
  • Velasco, Eladio A.
RAD51D loss-of-function variants increase lifetime risk of breast and ovarian cancer. Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility genes. Herein, we have assessed the splicing and clinical impact of splice-site and exonic splicing enhancer (ESE) variants identified through the study of similar to 113,000 women of the BRIDGES cohort. A RAD51D minigene with exons 2-9 was constructed in splicing vector pSAD. Eleven BRIDGES splice-site variants (selected by MaxEntScan) were introduced into the minigene by site-directed mutagenesis and tested in MCF-7 cells. The 11 variants disrupted splicing, collectively generating 25 different aberrant transcripts. All variants but one produced negligible levels (<3.4%) of the full-length (FL) transcript. In addition, ESE elements of the alternative exon 3 were mapped by testing four overlapping exonic microdeletions (>= 30-bp), revealing an ESE-rich interval (c.202_235del) with critical sequences for exon 3 recognition that might have been affected by germline variants. Next, 26 BRIDGES variants and 16 artificial exon 3 single-nucleotide substitutions were also assayed. Thirty variants impaired splicing with variable amounts (0-65.1%) of the FL transcript, although only c.202G>A demonstrated a complete aberrant splicing pattern without the FL transcript. On the other hand, c.214T>C increased efficiency of exon 3 recognition, so only the FL transcript was detected (100%). In conclusion, 41 RAD51D spliceogenic variants (28 of which were from the BRIDGES cohort) were identified by minigene assays. We show that minigene-based mapping of ESEs is a powerful approach for identifying ESE hotspots and ESE-disrupting variants. Finally, we have classified nine variants as likely pathogenic according to ACMG/AMP-based guidelines, highlighting the complex relationship between splicing alterations and variant interpretation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Shared heritability and functional enrichment across six solid cancers

  • Jiang, Xia
  • Finucane, Hilary K.
  • Schumacher, Fredrick R.
  • Schmit, Stephanie L.
  • Tyrer, Jonathan P.
  • Han, Younghun
  • Michailidou, Kyriaki
  • Lesseur, Corina
  • Kuchenbaecker, Karoline B.
  • Dennis, Joe
  • Conti, David V.
  • Cunningham, Julie M.
  • John, Esther M.
  • Couch, Fergus J.
  • Bolla, Manjeet K.
  • Casey, Graham
  • Margolin, Sara
  • Goodman, Gary
  • Evans, D. Gareth
  • Riggan, Marjorie J.
  • Gago-Dominguez, Manuela
  • Jenkins, Mattias
  • Fostira, Florentia
  • Kaneva, Radka
  • Arnold, Susanne M.
  • Offit, Kenneth
  • Ruyck, Kim De
  • Olsson, Håkan
  • Arun, Banu K.
  • Schleutker, Johanna
  • Aronson, Kristan J.
  • Caligo, Maria A.
  • Tardón, Adonina
  • Edlund, Christopher K.
  • Ingles, Sue Ann
  • Hsu, Li
  • Rosenstein, Barry S.
  • Chenevix-Trench, Georgia
  • McKay, James D.
  • Claes, Kathleen B. M.
  • Chanock, Stephen J.
  • Nordestgaard, Børge G.
  • Park, Jong Y.
  • Kupryjanczyk, Jolanta
  • Cadoni, Gabriella
  • Neal, David E.
  • Diez, Orland
  • Ferris, Robert L.
  • Stefansson, Kari
  • Cannon-Albright, Lisa A.
  • Weinberg, Clarice R.
  • McGuffog, Lesley
  • Raskin, Leon
  • Mannermaa, Arto
  • Kibel, Adam S.
  • Neuhausen, Susan L.
  • Hulick, Peter J.
  • Shen, Hongbing
  • Wichmann, H-Erich
  • Goldberg, Mark S.
  • Greene, Mark H.
  • Maehle, Lovise
  • Yannoukakos, Drakoulis
  • Garber, Judy
  • Webb, Penelope M.
  • Weissler, Mark C.
  • Pejovic, Tanja
  • Bojesen, Stig E.
  • Toland, Amanda E.
  • Blomqvist, Carl
  • Knight, Julia A.
  • Huntsman, David G.
  • Dörk, Thilo
  • Gaudet, Mia M.
  • Hong, Yun-Chul
  • Whittemore, Alice S.
  • Torres, Diana
  • Hung, Rayjean J.
  • García-Closas, Montserrat
  • Li, Li
  • Friedman, Eitan
  • Hillemanns, Peter
  • Haugen, Aage
  • Cruz Correa, Marcia
  • Wolk, Alicja
  • Olopade, Olufunmilayo I.
  • Risch, Harvey A.
  • Terry, Kathryn L.
  • Hamdy, Freddie C.
  • Burwinkel, Barbara
  • Brauch, Hiltrud
  • Parsons, Michael T.
  • Tangen, Catherine M.
  • Travis, Ruth C.
  • Middha, Pooja
  • Terry, Mary Beth
  • Newcomb, Lisa F.
  • Nielsen, Finn C.
  • Ness, Andrew R.
  • Stanford, Janet L.
  • Kraft, Peter
  • Montagna, Marco
  • Brenton, James D.
  • Roobol, Monique J.
  • Thibodeau, Stephen N.
  • Sundfeldt, Karin
  • Hampe, Jochen
  • Lubiński, Jan
  • Tung, Nadine
  • Nevanlinna, Heli
  • Chang-Claude, Jenny
  • Stone, Jennifer
  • Swerdlow, Anthony J.
  • Brenner, Hermann
  • Wiklund, Fredrik
  • Bandera, Elisa V.
  • Siegel, Erin M.
  • Lester, Jenny
  • Le, Nhu D.
  • Taylor, Jack A.
  • Chan, Andrew T.
  • Donovan, Jenny L.
  • Landi, Maria Teresa
  • Aldrich, Melinda C.
  • White, Emily
  • Stevens, Victoria L.
  • Velez Edwards, Digna R.
  • Goodman, Marc T.
  • Easton, Douglas F.
  • Dwek, Miriam
  • Berchuck, Andrew
  • deFazio, Anna
  • Devilee, Peter
  • Heitz, Florian
  • Hopper, John L.
  • Hunter, David J.
  • Peters, Ulrike
  • Albanes, Jeroen R.
  • Singer, Christian F.
  • Woll, Penella
  • Tajara, Eloiza H.
  • Brunet, Joan
  • Christiani, David C.
  • Weitzel, Jeffrey N.
  • García-Sáenz, José A.
  • Liloglou, Triantafillos
  • Phipps, Amanda I.
  • Cybulski, Cezary
  • Li, Christopher I.
  • Lazarus, Philip
  • Sawyer, Elinor J.
  • Lane, Jacqueline M.
  • Meindl, Alfons
  • Liu, Geoffrey
  • Grankvist, Kjell
  • Peters, Wilbert H. M.
  • Goode, Ellen L.
  • Godwin, Andrew K.
  • Butzow, Ralf
  • Barkardottir, Rosa B.
  • Bien, Stephanie A.
  • Ulrich, Cornelia M.
  • Brunnström, Hans
  • Goldgar, David E.
  • Lee, Eunjung
  • Koutros, Stella
  • Setiawan, V. Wendy
  • Fletcher, Olivia
  • Moysich, Kirsten B.
  • Høgdall, Estrid
  • Gallinger, Steven
  • Lacko, Martin
  • Chen, Chu
  • Beckmann, Matthias W.
  • Elías Aguado-Barrera, Miguel
  • Barnes, Daniel R.
  • Imyanitov, Evgeny N.
  • Clements, Judith
  • Pandha, Hardev
  • Lenz, Heinz-Josef
  • MacInnis, Robert J.
  • Idos, Gregory
  • Daly, Mary B.
  • Anton-Culver, Hoda
  • Winqvist, Robert
  • Khusnutdinova, Elza
  • Muir, Kenneth
  • Diergaarde, Brenda
  • Collée, J. Margriet
  • Rossing, Mary Anne
  • Radice, Paolo
  • Bjørge, Line
  • Phelan, Catherine M.
  • Usmani, Nawaid
  • Brook, Mark N.
  • Rennert, Hedy S.
  • Lindo, Noralane M.
  • West, Catharine M. L.
  • Lam, Stephan
  • Teare, M. Dawn
  • Sandler, Dale P.
  • van Rensburg, Elizabeth J.
  • Levine, Douglas A.
  • Milne, Roger L.
  • Sorensen, Karina Dalsgaard
  • Sutphen, Rebecca
  • Miller, Austin
  • Isaacs, Claudine
  • Lesse, Davor
  • Zheng, Wei
  • Campbell, Peter T.
  • Olshan, Andrew F.
  • Modugno, Francesmary
  • Ramus, Susan J.
  • James, Paul
  • Cox, Angela
  • Caldés, Trinidad
  • Wang, Qin
  • Simard, Jacques
  • Schabath, Matthew B.
  • Pasaniuc, Bogdan
  • Carvalho, André L.
  • Lambrechts, Diether
  • Antonenkova, Natalia N.
  • Andrew, Angeline S.
  • Johansson, Mikael
  • Johansson, Mattias
  • Herrero, Rolando
  • Boccia, Stefania
  • Håkansson, Niclas
  • Kjaer, Susanne K.
  • Berndt, Sonja I.
  • Lejbkowicz, Flavio
  • Pharoah, Paul D. P.
  • Hamilton, Robert J.
  • Moreno Aguado, Víctor
  • Gruber, Stephen B.
  • Gronberg, Henrik
  • Kristensen, Vessela N.
  • Sieh, Weiva
  • Saxena, Richa
  • Bickeböller, Heike
  • Joshi, Amit D.
  • Olah, Edith
  • Zienolddiny, Shanbeh
  • Vega, Ana
  • Gayther, Simon A.
  • Campbell, Ian
  • Kühl, Tabea
  • Hall, Per
  • Rennert, Gad
  • Dunning, Alison M.
  • Czene, Kamila
  • Stintzing, Sebastian
  • Osorio, Ana
  • Hoffmeister, Michael
  • Spurdle, Amanda B.
  • Marchand, Loïc Le
  • Buchanan, Daniel D.
  • Slattery, Martha L.
  • Hamann, Ute
  • Caporaso, Neil E.
  • Kelemen, Linda E.
  • Mulligan, Anna Marie
  • Fortner, Renée T.
  • Weinstein, Stephanie
  • Penney, Kathryn L.
  • Mucci, Lorelei
  • Jakubowska, Anna
  • Nikitina-Zake, Liene
  • Loupakis, Fotios
  • Van Nieuwenhuysen, Els
  • Wu, Anna H.
  • Pashayan, Nora
  • Risch, Angela
  • Andrulis, Irene L.
  • Ganz, Patricia A.
  • Maier, Christiane
  • Wu, Xifeng
  • Khaw, Kay-Tee
  • Southey, Melissa C.
  • Townsend, Paul A.
  • Thomas, Duncan C.
  • Vachon, Celine M.
  • Eccles, Diana
  • Schmidt, Marjanka K.
  • Kote-Jarai, Zsofia
  • Campa, Daniele
  • Huyghe, Jeroen R.
  • Duell, Eric J.
  • Claessens, Frank
  • May, Taymaa
  • Houlston, Richard
  • Fasching, Peter A.
  • Kim, Jeri
  • Prokofyeva, Darya
  • Giles, Graham G.
  • Karlan, Beth Y.
  • Lindström, Sara
  • Antoniou, Antonis C.
  • Figueiredo, Jane C.
  • Kiemeney, Lambertus A. L. M.
  • Eeles, Rosalind A.
  • Kogevinas, Manolis
  • Bogdanova, Natalia V.
  • Guénel, Pascal
  • Gronwald, Jacek
  • Brennan, Paul
  • Batra, Jyotsna
  • Franceschi, Silvia
  • Lindblom, Annika
  • Amos, Christopher I.
  • Leslie, Goska
  • Thomassen, Mads
  • Haiman, Christopher A.
  • Nussbaum, Robert L.
  • Benlloch, Sara
  • Al Olama, Ali Amin
  • Pring, Miranda
  • Benitez, Javier
  • Ziogas, Argyrios
  • Cancel-Tassin, Géraldine
  • Price, Alkes L.
  • Woods, Michael
  • Tworoger, Shelley S.
  • Nathanson, Katherine L.
  • Ellberg, Carolina
  • Teixeira, Manuel R.
  • Saloustros, Emmanouil
  • Tischkowitz, Marc
  • Zorn, Kristin K.
  • Plaseska-Karanfilska, Dijana
  • Newcomb, Polly A.
Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10-8), breast and ovarian cancer (rg = 0.24, p = 7 × 10-5), breast and lung cancer (rg = 0.18, p =1.5 × 10-6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10-4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

  • Parsons, Michael T.
  • Tudini, Emma
  • Li, Hongyan
  • Hahnen, Eric
  • Wappenschmidt, Barbara
  • Feliubadaló i Elorza, Maria Lídia
  • Aalfs, Cora M.
  • Agata, Simona
  • Aittomäki, Kristiina
  • Alducci, Elisa
  • Alonso Cerezo, María Concepción
  • Hauke, Jan
  • Heinrich, Tilman
  • Törngren, Therese
  • Hellebrand, Heide
  • Arnold, Norbert
  • Seggewiß, Jochen
  • Caldés, Trinidad
  • Herold, Karen N.
  • Honisch, Ellen
  • Naldi, Nadia
  • Witzel, Isabell
  • Walters, Rhiannon J.
  • Rump, Andreas
  • Horvath, Judit
  • Poplawski, Nicola K.
  • Velasco, Àngela
  • Houdayer, Claude
  • Brunet, Joan
  • Cini, Giulia
  • Hübbel, Verena
  • Iglesias, Silvia
  • Wöckel, Achim
  • Steinemann, Doris
  • Izquierdo, Angel
  • Barbieri, Elena
  • Wang Gohrke, Shan
  • James, Paul A.
  • Carnevali, Ileana
  • Torres Esquius, Sara
  • Janssen, Linda A.M.
  • Jeschke, Udo
  • Kruse, Torben A.
  • Kölbl, Alexandra
  • Ledig, Susanne
  • Cops, Elisa J.
  • Vesper, Anne Sophie
  • Kaulfuß, Silke
  • Porfirio, Berardino
  • Auber, Bernd
  • Weber, Bernhard H. F.
  • Leinert, Elena
  • Rofes, Paula
  • Bruzzone, Carla
  • Woodward, Emma R.
  • Matricardi, Laura
  • Solanes, Ares
  • Carrasco, Estela
  • Mackelenbergh, Marion T.
  • Waha, Anke
  • Nathanson, Katherine L.
  • Tucker, Katherine M.
  • Bucksch, Karolin
  • Navarro, Matilde
  • Faust, Ulrike
  • Bonanni, Bernardo
  • González, Sara
  • Nevanlinna, Heli
  • Nichols, Cassandra B.
  • Cortesi, Laura
  • Wiesmüller, Lisa
  • Niederacher, Dieter
  • Vreeswijk, Maaike P. G.
  • Caux Moncoutier, Virginie
  • Nielsen, Henriette R.
  • Giesecke, Jutta
  • Hackmann, Karl
  • Azzollini, Jacopo
  • Ong, Kai Ren
  • Pachter, Nicholas
  • Galvao, Henrique C.R.
  • Couch, Fergus J.
  • Palmero, Edenir I.
  • Guerrieri Gonzaga, Aliana
  • Cagnoli, Giulia
  • Papi, Laura
  • Asperen, Christi J.
  • Pohl Rescigno, Esther
  • Ramser, Juliane
  • Cavalli, Pietro
  • Pedersen, Inge Søkilde
  • Wagner, Sebastian A.
  • Felbor, Ute
  • Darder, Esther
  • Reis, Rui M.
  • Wieland, Kerstin
  • Gismondi, Viviana
  • Blümcke, Britta
  • Zachariae, Silke
  • Calvello, Mariarosaria
  • Stiller, Mathias
  • Bartram, Claus R.
  • Feroce, Irene
  • Stoppa-Lyonnet, Dominique
  • Keupp, Katharina
  • Hoya, Miguel
  • Lucci Cordisco, Emanuela
  • Sullivan, Kelly J.
  • Susman, Rachel
  • Zampiga, Valentina
  • Guillaud Bataille, Marine
  • Concolino, Paola
  • Sutter, Christian
  • Caliebe, Almuth
  • Gómez, Carolina
  • Tavtigian, Sean V.
  • Lewis, Alexandra L.
  • Montagna, Marco
  • Teo, Soo H.
  • Teulé, Alex
  • Debatin, Irmgard
  • Thomassen, Mads
  • Kvist, Anders
  • Gutiérrez Enríquez, Sara
  • Tibiletti, Maria Grazia
  • Meindl, Alfons
  • Fine, Miriam
  • Tischkowitz, Marc
  • Blanco, Ana
  • Toss, Angela
  • Varesco, Liliana
  • Montes, Eva
  • Garcia, Encarna B.
  • Tognazzo, Silvia
  • Caligo, Maria A.
  • Kiechle, Marion
  • Haaf, Thomas
  • Vargas Parra, Gardenía María
  • Clarke, Edward M.
  • Lim, Joanna
  • Bonache, Sandra
  • Dean, Michael
  • Michelli, Rodrigo D.
  • Gensini, Francesca
  • Gross, Eva
  • Zeder Göß, Christine
  • Gambino, Gaetana
  • Loeffler, Markus
  • Investigators, Kconfab
  • Peissel, Bernard
  • Rivera, Daniela
  • Lázaro García, Conxi
  • Nicolo, Arcangela
  • Mori, Luigi
  • Harris, Marion
  • Radice, Paolo
  • Grau Garcés, Èlia
  • Moghadasi, Setareh
  • Engel, Christoph
  • Revillion, Françoise
  • Krieger, Sophie
  • Schmutzler, Rita Katharina
  • Goldgar, David E.
  • Balmaña, Judith
  • Austin, Rachel
  • Borg, Åke
  • Salinas, Monica
  • López Fernández, Adrià
  • Spurdle, Amanda B.
  • Gehrig, Andrea
  • Capone, Gabriele L.
  • Moles Fernández, Alejandro
  • Bortesi, Beatrice
  • Grill, Sabine
  • Pérez Segura, Pedro
  • Moserle, Lidia
  • Caputo, Sandrine M.
  • Hansen, Thomas V.O.
  • Rhiem, Kerstin
  • Lattimore, Vanessa L.
  • Marabelli, Monica
  • Del Valle, Jesús
  • Lalloo, Fiona
  • Pfeifer, Katharina
  • Delnatte, Capucine
  • Toland, Amanda E.
  • Müller, Clemens R.
  • Viel, Alessandra
  • Derive, Nicolas
  • Diez, Orland
  • Sánchez de Abajo, Ana María
  • Monteiro, Alvaro N.
  • Ditsch, Nina
  • Maass, Nicolai
  • Riboli, Barbara
  • Domchek, Susan M.
  • Varon-Mateeva, Raymonda
  • Weichert, Wilko
  • Dutrannoy, Véronique
  • Eccles, Diana
  • Ehrencrona, Hans
  • Trainer, Alison H.
  • Schmidt, Gunnar
  • Enders, Ute
  • Walker, Logan C.
  • Pineda Riu, Marta
  • Evans, D. Gareth
  • Larsen, Mirjam
  • Foulkes, William D.
  • Gerdes, Anne Marie
  • Ritter, Julia
  • Farra, Chantal
  • Manoukian, Siranoush
  • Tornero, Eva
  • Schoenwiese, Ulrike
  • Germani, Aldo
  • Montalban, Gemma
  • Vega, Ana
  • Lautrup, Charlotte
  • Mundhenke, Christoph
  • Quante, Anne S.
The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing BRCA1 and BRCA2 variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2 predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

  • Schmutzler, Rita
  • Schmitz-Luhn, Bjoern
  • Borisch, Bettina
  • Devilee, Peter
  • Eccles, Diana M
  • Hall, Per
  • Balmaña Gelpí, Judith
Breast cancer; Evidence-generating care; Risk-adjusted prevention, Cáncer de mama; Atención generadora de evidencia; Prevención ajustada al riesgo, Càncer de mama; Atenció generadora d'evidències; Prevenció ajustada al risc, Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept., The project was funded by the German Federal Ministry of Health (grant No. 2515FSB401 to Rita Schmutzler and Christiane Woopen) for supporting the international expert meetings, and a grant of the EU Horizon 2020 program, BRIDGES (grant No. 634935, PI Peter Devilee, WP5-PI Rita Schmutzler), for the compilation of the most recent findings of genetic risk prediction.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model

  • Mavaddat, Nasim
  • Ficorella, Lorenzo
  • Carver, Tim
  • Lee, Andrew
  • Cunningham, Alex P.
  • Pardo Muñoz, Monica
  • Balmaña Gelpí, Judith
  • Lush, Michael
Polygenic risk; Prediction; Breast cancer, Riesgo poligénico; Predicción; Cáncer de mama, Risc poligènic; Predicció; Càncer de mama, Background: The multifactorial risk prediction model BOADICEA enables identification of women at higher or lower risk of developing breast cancer. BOADICEA models genetic susceptibility in terms of the effects of rare variants in breast cancer susceptibility genes and a polygenic component, decomposed into an unmeasured and a measured component - the polygenic risk score (PRS). The current version was developed using a 313 SNP PRS. Here, we evaluated approaches to incorporating this PRS and alternative PRS in BOADICEA. Methods: The mean, SD, and proportion of the overall polygenic component explained by the PRS (α2) need to be estimated. α was estimated using logistic regression, where the age-specific log-OR is constrained to be a function of the age-dependent polygenic relative risk in BOADICEA; and using a retrospective likelihood (RL) approach that models, in addition, the unmeasured polygenic component. Results: Parameters were computed for 11 PRS, including 6 variations of the 313 SNP PRS used in clinical trials and implementation studies. The logistic regression approach underestimates α⁠, as compared with the RL estimates. The RL α estimates were very close to those obtained by assuming proportionality to the OR per 1 SD, with the constant of proportionality estimated using the 313 SNP PRS. Small variations in the SNPs included in the PRS can lead to large differences in the mean. Conclusions: BOADICEA can be readily adapted to different PRS in a manner that maintains consistency of the model., This work has been supported by grants from Cancer Research UK (PPRPGM-Nov20\100002); the European Union's Horizon 2020 Research and Innovation Programme under grant agreement numbers 633784 (B-CAST) and 634935 (BRIDGES); the PERSPECTIVE I&I project which is funded by the Government of Canada through Genome Canada (#13529) and the Canadian Institutes of Health Research (#155865), the Ministère de l’Économie et de l'Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund; and by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20014). BCAC is funded by the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and the PERSPECTIVE I&I project. Additional funding for BCAC is provided via the Confluence project which is funded with intramural funds from the NCI Intramural Research Program, NIH. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer Research UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l’Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. MT was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20014) and Cancer Research UK C22770/A31523 (International Alliance for Cancer Early Detection programme). The PRISMA study has been funded by Instituto de Salud Carlos III through the project " PI19/01195″ (Co-funded by European Regional Development Fund "A way to make Europe") and it received the institutional support of CERCA Program (Generalitat de Catalunya). The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez-Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Pujana Genestar, M. Ángel
  • Teulé-Vega, Àlex
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • KConFab Investigators
  • HEBON Investigators
  • ABCTB Investigators
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

  • Lázaro García, Conxi
  • ProCURE
  • Genetic Counseling Unit, Hereditary Cancer Program
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease(1). We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 x 10(-8) with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

  • Lázaro García, Conxi
  • GC-HBOC Study Collaborators
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • HEBON Investigators
  • BCFR Investigators
  • ABCTB Investigators
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into the etiology of breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results, an observational prospective study

  • Brédart, Anne|||0000-0002-1864-5371
  • Kop, Jean-Luc|||0000-0002-6963-8411
  • Dick, Julia|||0000-0003-3325-7892
  • Cano, Alejandra
  • De Pauw, Antoine|||0000-0003-3898-073X
  • Anota, Amélie
  • Brunet, Joan|||0000-0003-1945-3512
  • Devilee, Peter|||0000-0002-8023-2009
  • Stoppa-Lyonnet, Dominique|||0000-0002-5438-8309
  • Schmutzler, Rita
  • Dolbeault, Sylvie
Objectives and setting Advances in multigene panel testing for cancer susceptibility has increased the complexity of counselling, requiring particular attention to counselees' psychosocial needs. Changes in psychosocial problems before and after genetic testing were prospectively compared between genetic test results in women tested for breast or ovarian cancer genetic susceptibility in French, German and Spanish clinics. Participants and measures Among 752 counselees consecutively approached, 646 (86%) were assessed after the initial genetic consultation (T1), including 510 (68%) affected with breast cancer, of which 460 (61%) were assessed again after receiving the test result (T2), using questionnaires addressing genetic-specific psychosocial problems (Psychosocial Aspects of Hereditary Cancer (PAHC)-six scales). Sociodemographic and clinical data were also collected. Results Seventy-nine (17.2%), 19 (4.1%), 259 (56.3%), 44 (9.6%) and 59 (12.8%) women received a BRCA1/2, another high/moderate-risk pathogenic variant (PV), negative uninformative, true negative (TN) or variant of uncertain significance result (VUS), respectively. On multiple regression analyses, compared with women receiving another result, those with a VUS decreased more in psychosocial problems related to hereditary predisposition (eg, coping with the test result) (ß=-0.11, p<0.05) and familial/social issues (eg, risk communication) (ß=-0.13, p<0.05), almost independently from their problems before testing. Women with a PV presented no change in hereditary predisposition problems and, so as women with a TN result, a non-significant increase in familial/social issues. Other PAHC scales (ie, emotions, familial cancer, personal cancer and children-related issues) were not affected by genetic testing. Conclusions In women tested for breast or ovarian cancer genetic risk in European genetics clinics, psychosocial problems were mostly unaffected by genetic testing. Apart from women receiving a VUS result, those with another test result presented unchanged needs in counselling in particular about hereditary predisposition and familial/social issues
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessment of psychosocial difficulties by genetic clinicians and distress in women at high risk of breast cancer, a prospective study

  • Brédart, Anne|||0000-0002-1864-5371
  • Kop, Jean-Luc|||0000-0002-6963-8411
  • Tüchler, Anja|||0000-0001-9985-8397
  • De Pauw, Antoine|||0000-0003-3898-073X
  • Cano, Alejandra
  • Dick, Julia|||0000-0003-3325-7892
  • Rhiem, Kerstin
  • Devilee, Peter|||0000-0002-8023-2009
  • Schmutzler, Rita
  • Stoppa-Lyonnet, Dominique|||0000-0002-5438-8309
  • Dolbeault, Sylvie
We examined how often genetic clinicians correctly identify psychosocial difficulties in women at high breast cancer risk and explored effects of this assessment and the genetic test result on counselees' distress. A prospective observational study of counselee-clinician dyads was performed in three French, German and Spanish genetic clinics, involving 709 counselees (participation rate, 83.4%) and 31 clinicians (participation rate, 100%). Counselee-clinician agreement in perceived psychosocial difficulties was measured after the pre-test genetic consultation. Multivariate mixed linear models accounting for clinicians were tested. Predicted distress levels were assessed after the pre- (T1) and post-test result disclosure consultations (T2). Depending on the difficulty domain, clinicians adequately assessed the presence or absence of difficulties in 51% ("familial issues") to 59% ("emotions") of counselees. When counselees' and clinicians' perceptions disagreed, difficulties were generally underestimated by clinicians. Counselees' distress levels remained stable from T1 to T2, irrespective of clinicians' appraisal adequacy, and the genetic test result disclosure. Psychological referral need were found in 20-42% of counselees, more frequently observed for difficulties in the "emotions" domain. Our findings suggest that the genetic test result is a suboptimal indicator for psychological referral. Instead, clinicians should focus on emotions expressed by counselees to appraise their needs for psychological support.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A saturated map of common genetic variants associated with human height

  • Yengo, Loic|||0000-0002-4272-9305
  • Vedantam, Sailaja|||0000-0003-3892-7461
  • Marouli, Eirini|||0000-0001-6179-1609
  • Sidorenko, Julia
  • Bartell, Eric
  • Sakaue, Saori|||0000-0003-3618-9717
  • Graff, Marielisa
  • Eliasen, Anders U.
  • Jiang, Yunxuan
  • Raghavan, Sridharan
  • Miao, Jenkai
  • Arias, Joshua D.
  • Graham, Sarah E.|||0000-0003-1271-2489
  • Mukamel, Ronen E.
  • Spracklen, Cassandra N.|||0000-0003-3590-7182
  • Yin, Xianyong|||0000-0001-6454-2384
  • Chen, Shyh-Huei
  • Ferreira, Teresa
  • Highland, Heather H.
  • Ji, Yingjie
  • Karaderi, Tugce|||0000-0001-9763-8139
  • Lin, Kuang
  • Lüll, Kreete
  • Malden, Deborah|||0000-0003-0567-8294
  • Medina-Gomez, Carolina|||0000-0001-7999-5538
  • Machado, Moara
  • Moore, Amy
  • Rüeger, Sina
  • Sim, Xueling|||0000-0002-1233-7642
  • Vrieze, Scott
  • Ahluwalia, Tarunveer Singh|||0000-0002-7464-3354
  • Akiyama, Masato|||0000-0002-1879-5476
  • Allison, Matthew A.
  • Álvarez, Marcus
  • Andersen, Mette korre|||0000-0001-8227-1469
  • Ani, Alireza|||0000-0002-7868-3118
  • Appadurai, Vivek
  • Arbeeva, Liubov|||0000-0001-5004-419X
  • Bhaskar, Seema
  • Bielak, Lawrence F.|||0000-0002-3443-8030
  • Bollepalli, Sailalitha|||0000-0002-8773-7149
  • Bonnycastle, Lori L.
  • Bork-Jensen, Jette
  • Bradfield, Jonathan Paul|||0000-0001-8758-2071
  • Bradford, Yuki
  • Braund, Peter S.|||0000-0001-8540-5709
  • Brody, Jennifer A.|||0000-0001-8509-148X
  • Burgdorf, Kristoffer S.
  • Cade, Brian E.|||0000-0003-1424-0673
  • Cai, H.
  • Cai, Qiuyin
  • Campbell, Archie|||0000-0003-0198-5078
  • Cañadas-Garre, Marisa|||0000-0003-1103-5658
  • Catamo, Eulalia|||0000-0002-4701-9134
  • Chai, Jin-Fang|||0000-0003-3770-1137
  • Chai, Xiaoran
  • Chang, Liching
  • Chang, Yicheng
  • Chen, Chien Hsiun
  • Chesi, Alessandra|||0000-0002-0954-7446
  • Choi, Seunghoan
  • Chung, Renhua
  • Cocca, Massimiliano|||0000-0002-1127-7596
  • Concas, Maria Pina|||0000-0003-3598-2537
  • Couture, Christian Y.
  • Cuellar-Partida, Gabriel|||0000-0001-7648-4097
  • Danning, Rebecca D.
  • Daw, E. Warwick
  • Degenhard, Frauke
  • Delgado, Graciela E.|||0000-0002-1272-7210
  • Delitala, Alessandro|||0000-0003-1729-8969
  • Demirkan, Ayşe|||0000-0002-7546-0867
  • Deng, Xuan|||0000-0003-0918-817X
  • Devineni, Poornima
  • Dietl, Alexander|||0000-0002-4091-8620
  • Dimitriou, Maria E.
  • Dimitrov, Latchezar M.
  • Dorajoo, Rajkumar|||0000-0001-6608-2051
  • Ekici, Arif B.
  • Engmann, Jorgen|||0000-0001-7015-7773
  • Fairhurst-Hunter, Zammy
  • Farmaki, Aliki Eleni
  • Faul, Jessica D.|||0000-0002-6969-6478
  • Fernandez-Lopez, Juan Carlos|||0000-0003-3680-4193
  • Forer, Lukas|||0000-0003-2139-7329
  • Francescatto, Margherita
  • Freitag-Wolf, Sandra
  • Fuchsberger, Christian|||0000-0002-5918-8947
  • Galesloot, Tessel E.
  • Gao, Yan
  • Gao, Zishan|||0000-0003-1299-0286
  • Geller, Frank
  • Giannakopoulou, Olga
  • Giulianini, Franco
  • Gjesing, Anette Prior
  • Goel, Anuj|||0000-0003-2307-4021
  • Gordon, Scott D.|||0000-0001-7623-328X
  • Gorski, Mathias M.
  • Grove, Jakob|||0000-0003-2284-5744
  • Guo, Xiuqing
  • Gustafsson, S.|||0000-0001-5894-0351
  • Haessler, Jeffrey W.
  • Hansen, Thomas Folkmann
  • Havulinna, Aki Samuli
  • Haworth, S.J.
  • He, Jing
  • Heard-Costa, Nancy L.
  • Hebbar, Prashantha|||0000-0001-6560-7063
  • Hindy, George|||0000-0002-7257-9299
  • Ho, Yuk Lam Anne
  • Hofer, Edith
  • Holliday, Elizabeth|||0000-0002-4066-6224
  • Horn, Katrin
  • Hornsby, Whitney E.
  • Hottenga, Jouke Jan|||0000-0002-5668-2368
  • Huang, Hongyan
  • Huang, Jie
  • Huerta-Chagoya, Alicia|||0000-0001-6218-3904
  • Huffman, Jennifer E.|||0000-0002-9672-2491
  • Hung, Yijen
  • Huo, Shaofeng
  • Hwang, Mi-yeong
  • Iha, Hiroyuki|||0000-0003-4261-2067
  • Ikeda, Daisuke D.|||0000-0001-8403-0327
  • Isono, Masato
  • Jackson, Anne U.|||0000-0002-9672-2547
  • Jäger, Susanne
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Johansson, Ingegerd
  • Jonas, Jost Bruno
  • Jonsson, Anna Elisabet
  • Jørgensen, Torben J.
  • Kalafati, IP.|||0000-0001-5572-7491
  • Kanai, Masahiro|||0000-0001-5165-4408
  • Kanoni, Stavroula|||0000-0002-1691-9615
  • Kårhus, Line Lund
  • Kasturiratne, Anuradhani
  • Katsuya, Tomohiro|||0000-0002-8892-8828
  • Kawaguchi, Takahisa
  • Kember, Rachel L.|||0000-0001-8820-2659
  • Kentistou, Katherine A.|||0000-0002-5816-664X
  • Kim, Hanna
  • Kim, Young-jin
  • Kleber, Marcus Edi
  • Knol, Maria J.|||0000-0002-3597-1531
  • Kurbasic, Azra
  • Lauzon, Marie
  • Le, Phuong
  • Lea, Rodney A.
  • Lee, Jongyoung
  • Leonard, Hampton L.|||0000-0003-2390-8110
  • Li, Shengchao Alfred
  • Li, Xiaoyin
  • Liang, Jingjing
  • Lin, Honghuang
  • Lin, Shihyi
  • Liu, Jun|||0000-0001-5288-3042
  • Liu, Xueping
  • Lo, Ken Sin
  • Long, Jirong
  • Lores-Motta, Laura
  • Luan, Jian'fan N. An
  • Lyssenko, Valeriya
  • Lyytikäinen, Leo Pekka
  • Mahajan, Anubha|||0000-0001-5585-3420
  • Mamakou, Vasiliki
  • Mangino, Massimo
  • Manichaikul, Ani W.
  • Marten, Jonathan|||0000-0001-6916-2014
  • Mattheisen, Manuel|||0000-0002-8442-493X
  • Mavarani, Laven
  • McDaid, Aaron F.
  • Meidtner, Karina
  • Melendez, Tori L.
  • Mercader, Josep M.|||0000-0001-8494-3660
  • Milaneschi, Yuri|||0000-0002-3697-6617
  • Miller, Jason E.
  • Millwood, Iona Y.
  • Mishra, Pashupati P.|||0000-0001-5177-3431
  • Mitchell, Ruth E.
  • Møllehave, Line Tang|||0000-0001-7116-9346
  • Morgan, Anna
  • Mucha, Soeren
  • Munz, Matthias|||0000-0002-4728-3357
  • Nakatochi, Masahiro|||0000-0002-1838-4837
  • Nelson, Christopher P.
  • Nethander, Maria
  • Nho, Chu Won
  • Nielsen, Aneta A.
  • Nolte, Ilja M.|||0000-0001-5047-4077
  • Nongmaithem, Suraj S.|||0000-0001-5390-0449
  • Noordam, Raymond|||0000-0001-7801-809X
  • Ntalla, Ioanna
  • Nutile, Teresa
  • Pandit, Anita
  • Christofidou, Paraskevi
  • Pärna, Katri
  • Pauper, Marc
  • Petersen, Eva R.B.
  • Petersen, Liselotte V.
  • Pitkänen, Niina
  • Polašek, Ozren
  • Poveda, Alaitz|||0000-0001-6349-3955
  • Preuss, Michael H.
  • Pyarajan, Saiju
  • Raffield, Laura M.
  • Rakugi, Hiromi
  • Ramirez, Julia
  • Rasheed, Asif
  • Raven, Dennis
  • Rayner, Nigel W.
  • Riveros, Carlos
  • Rohde, Rebecca
  • Ruggiero, Daniela|||0000-0003-3898-7827
  • Ruotsalainen, Sanni E.|||0000-0002-1631-4069
  • Ryan, Kathleen A.
  • Sabater-Lleal, Maria|||0000-0002-0128-379X
  • Saxena, Richa
  • Scholz, Markus|||0000-0002-4059-1779
  • Sendamarai, Anoop
  • Shen, Botong
  • Shi, Jingchunzi
  • Shin, J.H.
  • Sidore, Carlo|||0000-0001-7504-7477
  • Sitlani, Collen M.|||0000-0001-7656-7482
  • Slieker, Roderick C.
  • Smit, Roelof A. J.
  • Smith, Albert V.
  • Smith, Jennifer A.|||0000-0002-3575-5468
  • Smyth, Laura J.|||0000-0001-6419-4826
  • Southam, Lorraine
  • Steinthorsdottir, Valgerdur
  • Sun, Liang
  • Takeuchi, Fumihiko
  • Tallapragada, Divya Sri Priyanka
  • Taylor, Kent|||0000-0002-2756-4370
  • Tayo, Bamidele O.
  • Tcheandjieu, Catherine
  • Terzikhan, Natalie
  • Tesolin, Paola|||0000-0002-5238-6422
  • Teumer, Alexander|||0000-0002-8309-094X
  • Theusch, Elizabeth|||0000-0002-5678-759X
  • Thompson, Deborah J.
  • Thorleifsson, Gudmar|||0000-0003-4623-9087
  • Timmers, Paul R. H. J.
  • Trompet, Stella|||0000-0001-5006-0528
  • Turman, Constance
  • Vaccargiu, Simona
  • van der Laan, Sander W.|||0000-0001-6888-1404
  • van der Most, Peter J.|||0000-0001-8450-3518
  • van Klinken, Jan Bert
  • van Setten, Jessica A.
  • Verma, Shefali Setia
  • Verweij, Niek|||0000-0002-4303-7685
  • Veturi, Yogasudha C.
  • Wang, Carol A.|||0000-0002-4301-3974
  • Wang, Chaolong
  • Wang, Lihua
  • Wang, Zhe|||0000-0003-0786-9887
  • Warren, Helen R.
  • Bin Wei, Wen
  • Wickremasinghe, Ananda|||0000-0002-6174-6784
  • Wielscher, Matthias|||0000-0003-4138-1383
  • Wiggins, Kerri L.|||0000-0003-2749-1279
  • Winsvold, Bendik Slagsvold|||0000-0003-4171-8919
  • Wong, Andrew|||0000-0003-2079-4779
  • Wu, Yang|||0000-0002-0128-7280
  • Wuttke, Matthias|||0000-0003-3420-5082
  • Xia, Rui|||0000-0003-2409-1181
  • Xie, Tian
  • Yamamoto, Ken
  • Yang, Jingyun
  • Yao, Jie
  • Young, Hannah|||0000-0002-4248-9612
  • Yousri, Noha A.|||0000-0003-1918-0331
  • Yu, Lei
  • Zeng, Lingyao
  • Zhang, Weihua
  • Zhang, Xinyuan
  • Zhao, Jinghua
  • Zhao, Wei|||0000-0002-4839-6791
  • Zhou, Wei
  • Zimmermann, Martina E.|||0000-0002-6916-4404
  • Zoledziewska, Magdalena|||0000-0002-3033-6133
  • Adair, Linda S.
  • Adams, Hieab H. H.|||0000-0003-3687-2508
  • Aguilar-Salinas, Carlos Alberto
  • Al-Mulla, Fahd|||0000-0001-5409-3829
  • Arnett, Donna|||0000-0003-2219-657X
  • Asselbergs, Folkert W.|||0000-0002-1692-8669
  • Åsvold, Bjørn Olav|||0000-0003-3837-2101
  • Attia, John Richard
  • Banas, Bernhard|||0000-0003-2076-2195
  • Bandinelli, Stefania|||0000-0002-6491-0850
  • Bennett, David Alan
  • Bergler, Tobias
  • Bharadwaj, Dwaipayan
  • Biino, Ginevra|||0000-0002-9936-946X
  • Bisgaard, Hans
  • Boerwinkle, Eric|||0000-0001-8813-0544
  • Böger, Carsten A.
  • Bønnelykke, Klaus
  • Boomsma, Dorret I.|||0000-0002-7099-7972
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Borja, Judith B.
  • Bouchard, Claude|||0000-0002-0048-491X
  • Bowden, Donald W.
  • Brandslund, Ivan
  • Brumpton, Ben
  • Buring, Julie E.
  • Caulfield, Mark|||0000-0001-9295-3594
  • Chambers, John C.
  • Chandak, Giriraj R.
  • Chanock, Stephen|||0000-0002-2324-3393
  • Chaturvedi, Nish
  • Chen, Yii Der Ida
  • Chen, Zhengming|||0000-0001-6423-105X
  • Cheng, Ching-Yu|||0000-0003-0655-885X
  • Christophersen, Ingrid E.
  • Ciullo, Marina|||0000-0002-9621-9984
  • Cole, John W.|||0000-0001-9263-8930
  • Collins, Francis S.|||0000-0002-1023-7410
  • Cooper, Richard S.
  • Cruz, Miguel
  • Cucca, Francesco|||0000-0002-7414-1995
  • Cupples, L. Adrienne
  • Cutler, Michael J.
  • Damrauer, Scott M.|||0000-0001-8009-1632
  • Dantoft, Thomas M.
  • de Borst, Gert J.
  • de Groot, Lisette C.P.G.M.|||0000-0003-2778-2789
  • De Jager, Philip L.|||0000-0002-8057-2505
  • de Kleijn, D.P.V.|||0000-0003-2714-2140
  • Janaka de Silva, H.
  • Dedoussis, George V.
  • den Hollander, Anneke I.
  • Du, Shufa
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Elders, Petra J. M.
  • Eliassen, A. Heather Heather
  • Ellinor, Patrick T.
  • Elmståhl, Sölve
  • Erdmann, Jeanette|||0000-0002-4486-6231
  • Evans, Michele K.
  • Fatkin, Diane
  • Feenstra, Bjarke|||0000-0003-1478-649X
  • Feitosa, Mary|||0000-0002-0933-2410
  • Ferrucci, Luigi
  • Ford, Ian
  • Fornage, Myriam|||0000-0003-0677-8158
  • Franke, Andre|||0000-0003-1530-5811
  • Franks, Paul W.|||0000-0002-0520-7604
  • Freedman, Barry I.|||0000-0003-0275-5530
  • Gasparini, Paolo
  • Gieger, Christian|||0000-0001-6986-9554
  • Girotto, Giorgia|||0000-0003-4507-6589
  • Goddard, Michael E.
  • Golightly, Yvonne M.
  • Gonzalez-Villalpando, Clicerio
  • Gordon-Larsen, P.
  • Grallert, H.
  • Grant, Struan F. A.|||0000-0003-2025-5302
  • Grarup, Niels|||0000-0001-5526-1070
  • Griffiths, L.
  • Gudnason, V.
  • Haiman, C.
  • Hakonarson, Hakon|||0000-0003-2814-7461
  • Hansen, Torben|||0000-0001-8748-3831
  • Hartman, C.A.
  • Hattersley, A.T.
  • Hayward, Caroline|||0000-0002-9405-9550
  • Heckbert, S.R.
  • Heng, C.K.
  • Hengstenberg, C.
  • Hewitt, Alex W.|||0000-0002-5123-5999
  • Hishigaki, H.
  • Hoyng, C.B.
  • Huang, Paul L.
  • Huang, W.
  • Hunt, S.C.
  • Hveem, K.
  • Hyppönen, E.
  • Iacono, William
  • Ichihara, S.
  • Ikram, M.A.
  • Isasi, C.R.
  • Jackson, R.D.
  • Jarvelin, Marjo-Riitta|||0000-0002-2149-0630
  • Jin, Zi-Bing
  • Jöckel, K.H.
  • Joshi, P.K.
  • Jousilahti, P.
  • Jukema, J.W.
  • Kähönen, M.
  • Kamatani, Yoichiro|||0000-0001-8748-5597
  • Kang, K.D.
  • Kaprio, Jaakko|||0000-0002-3716-2455
  • Kardia, S.L.R.
  • Karpe, F.
  • Kato, N.
  • Kee, F.
  • Kessler, T.
  • Khera, Amit V.
  • Khor, C.C.
  • Kiemeney, Lambertus A.
  • Kim, B.J.
  • Kim, E.K.
  • Kim, H.L.
  • Kirchhof, P.
  • Kivimaki, Mika|||0000-0002-4699-5627
  • Koh, W.P.
  • Koistinen, H.A.
  • Kolovou, G.D.
  • Kooner, J.S.
  • Kooperberg, C.
  • Köttgen, A.
  • Kovacs, P.
  • Kraaijeveld, A.
  • Kraft, Peter
  • Krauss, R.M.
  • Kumari, M.
  • Kutalik, Zoltan|||0000-0001-8285-7523
  • Laakso, Markku|||0000-0002-3394-7749
  • Lange, Leslie A.
  • Langenberg, C.
  • Launer, L.J.
  • Le Marchand, L.
  • Lee, H.
  • Lee, N.R.
  • Lehtimäki, T.
  • Li, H.
  • Li, L.
  • Lieb, Wolfgang|||0000-0003-2544-4460
  • Lin, X.
  • Lind, Lars
  • Linneberg, Allan|||0000-0002-0994-0184
  • Liu, Ching-Ti
  • Liu, Jianjun|||0000-0002-3255-3019
  • Loeffler, Markus
  • London, Barry
  • Lubitz, Steven A.
  • Lye, Stephen J.
  • Mackey, David A.
  • Mägi, Reedik
  • Magnusson, Patrik K. E.|||0000-0002-7315-7899
  • Marcus, Gregory M.|||0000-0001-5197-7696
  • Vidal, Pedro M.
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • März, Winfried|||0000-0001-6083-8946
  • Matsuda, Fumihiko
  • McGarrah, Robert W.
  • McGue, Matt|||0000-0002-5580-1433
  • McKnight, Amy Jayne|||0000-0002-7482-709X
  • Medland, Sarah Elizabeth|||0000-0003-1382-380X
  • Mellström, Dan|||0000-0003-2761-3723
  • Metspalu, Andres|||0000-0002-3718-796X
  • Mitchell, Braxton|||0000-0003-4920-4744
  • Mitchell, Paul
  • Mook-Kanamori, Dennis O.
  • Morris, Andrew D.
  • Mucci, Lorelei A.
  • Munroe, Patricia B.|||0000-0002-4176-2947
  • Nalls, Mike A.
  • Nazarian, Saman
  • Nelson, Amanda E.
  • Neville, Matt J.|||0000-0002-6004-5433
  • Newton-Cheh, Christopher
  • Nielsen, Christopher S.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Ohlsson, Claes|||0000-0002-9633-2805
  • Oldehinkel, Albertine J.|||0000-0003-3925-3913
  • Orozco, Lorena|||0000-0002-5801-9180
  • Pahkala, Katja
  • Pajukanta, Päivi
  • Palmer, Colin N. A.
  • Parra, Esteban J.|||0000-0002-2057-8577
  • Pattaro, Cristian|||0000-0002-4119-0109
  • Pedersen, Oluf
  • Pennell, Craig E.|||0000-0002-0937-6165
  • Penninx, Brenda W. J. H.
  • Pérusse, Louis|||0000-0001-6440-9698
  • Peters, Annette|||0000-0001-6645-0985
  • Peyser, Patricia A.
  • Porteous, David J.|||0000-0003-1249-6106
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Power, Chris
  • Pramstaller, Peter P.
  • Province, Michael A.|||0000-0001-6102-774X
  • Qi, Qibin
  • Qu, Jia
  • Rader, Daniel J.
  • Raitakari, Olli T.
  • Ralhan, Sarju
  • Rallidis, Loukianos S.
  • Rao, Dabeeru C.
  • Redline, Susan
  • Reilly, Dermot F.
  • Reiner, Alexander P.
  • Rhee, Sang Youl|||0000-0003-0119-5818
  • Ridker, Paul M.
  • Rienstra, Michiel|||0000-0002-2581-070X
  • Ripatti, Samuli|||0000-0002-0504-1202
  • Ritchie, Marylyn D.|||0000-0002-1208-1720
  • Roden, Dan M.
  • Rosendaal, Frits|||0000-0003-2558-7496
  • Rotter, Jerome I.|||0000-0001-7191-1723
  • Rudan, Igor|||0000-0001-6993-6884
  • Rutters, Femke
  • Sabanayagam, Charumathi|||0000-0002-4042-4719
  • Saleheen, Danish|||0000-0001-6193-020X
  • Salomaa, Veikko|||0000-0001-7563-5324
  • Samani, Nilesh J.
  • Sanghera, Dharambir K.
  • Sattar, Naveed|||0000-0002-1604-2593
  • Schmidt, Börge
  • Schmidt, Helena|||0000-0001-9773-9992
  • Schmidt, Reinhold
  • Schulze, Matthias B.
  • Schunkert, Heribert|||0000-0001-6428-3001
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Sever, Peter
  • Shiroma, Eric J.
  • Shoemaker, M. Benjamin
  • Shu, Xiao-Ou
  • Simonsick, Eleanor M.
  • Sims, Mario
  • Singh, Jai Rup
  • Singleton, Andrew B.|||0000-0001-5606-700X
  • Sinner, Moritz F.
  • Smith, J. Gustav
  • Snieder, Harold|||0000-0003-1949-2298
  • Spector, Tim|||0000-0002-9795-0365
  • Stampfer, Meir J.
  • Stark, Klaus J.
  • Strachan, David P.
  • 't Hart, Leen M.
  • Tabara, Yasuharu
  • Tang, Hua
  • Tardif, J.C.
  • Thanaraj, T.A.
  • Timpson, N.J.
  • Tönjes, A.
  • Tremblay, A.
  • Tuomi, T.
  • Tuomilehto, J.
  • Tusié-Luna, M.T.
  • Uitterlinden, André G.|||0000-0002-7276-3387
  • van Dam, Rob M.
  • van der Harst, Pim|||0000-0002-2713-686X
  • Van der Velde, Nathalie
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • van Schoor, N.M.
  • Vitart, Veronique|||0000-0002-4991-3797
  • Völker, U.
  • Vollenweider, P.
  • Völzke, Henry|||0000-0001-7003-399X
  • Wacher-Rodarte, N.H.
  • Walker, M.
  • Wang, Y.X.
  • Wareham, N.J.
  • Watanabe, R.M.
  • Watkins, Hugh
  • Weir, D.R.
  • Werge, Thomas M.
  • Widen, E.
  • Wilkens, Lynne R.
  • Willemsen, Gonneke|||0000-0003-3755-0236
  • Willett, Walter C.
  • Wilson, James F.|||0000-0001-5751-9178
  • Wong, Tien-Yin
  • Woo, Jeong-Taek|||0000-0001-9201-0713
  • Wright, Alan F.
  • Wu, Jer-Yuarn
  • Xu, Huichun|||0000-0001-8118-9607
  • Yajnik, Chittaranjan S.
  • Yokota, Mitsuhiro
  • Yuan, Jian-Min|||0000-0002-4620-3108
  • Zeggini, Eleftheria|||0000-0003-4238-659X
  • Zemel, Babette S.
  • Zheng, Wei|||0000-0003-1226-070X
  • Zhu, X.|||0000-0003-0037-411X
  • Zmuda, Joseph M.
  • Zonderman, Alan B.|||0000-0002-6523-4778
  • Zwart, John-Anker|||0000-0001-5721-0154
  • Croteau-Chonka, Damien
  • Vonk, Judith M.
  • Le Marchand, Loic
  • Chasman, Daniel I.|||0000-0003-3357-0862
  • Cho, Yoon Shin
  • Heid, Iris M.
  • McCarthy, Mark I.
  • Ng, Maggie C. Y.
  • O'Donnell, Christopher J.
  • Rivadeneira, Fernando|||0000-0001-9435-9441
  • Thorsteinsdottir, Unnur
  • Sun, Yan V.|||0000-0002-2838-1824
  • Tai, E. Shyong
  • Boehnke, Michael|||0000-0002-6442-7754
  • Deloukas, Panos|||0000-0001-9251-070X
  • Justice, Anne E.
  • Lindgren, Cecilia M.
  • Loos, Ruth J. F.|||0000-0002-8532-5087
  • Mohlke, Karen L.|||0000-0001-6721-153X
  • North, Kari E.
  • Stefánsson, Kári|||0000-0003-1676-864X
  • Walters, Robin G.|||0000-0002-9179-0321
  • Winkler, Thomas W.|||0000-0003-0292-5421
  • Young, Kristin L.|||0000-0003-0070-6145
  • Loh, Po-Ru
  • Yang, Jian|||0000-0003-4800-832X
  • Esko, Tõnu
  • Assimes, Themistocles|||0000-0003-2349-0009
  • Auton, Adam
  • Abecasis, Goncalo
  • Willer, Cristen J.|||0000-0001-5645-4966
  • Locke, Adam E.|||0000-0001-6227-198X
  • Berndt, Sonja
  • Lettre, Guillaume
  • Frayling, Timothy M.
  • Okada, Yukinori|||0000-0002-0311-8472
  • Wood, Andrew R.|||0000-0003-1726-948X
  • Visscher, PM.|||0000-0002-2143-8760
  • Hirschhorn, Joel N.|||0000-0002-1650-7901
Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40-50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes. Here, using data from a genome-wide association study of 5.4 million individuals of diverse ancestries, we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP-based heritability. These SNPs are clustered within 7,209 non-overlapping genomic segments with a mean size of around 90 kb, covering about 21% of the genome. The density of independent associations varies across the genome and the regions of increased density are enriched for biologically relevant genes. In out-of-sample estimation and prediction, the 12,111 SNPs (or all SNPs in the HapMap 3 panel) account for 40% (45%) of phenotypic variance in populations of European ancestry but only around 10-20% (14-24%) in populations of other ancestries. Effect sizes, associated regions and gene prioritization are similar across ancestries, indicating that reduced prediction accuracy is likely to be explained by linkage disequilibrium and differences in allele frequency within associated regions. Finally, we show that the relevant biological pathways are detectable with smaller sample sizes than are needed to implicate causal genes and variants. Overall, this study provides a comprehensive map of specific genomic regions that contain the vast majority of common height-associated variants. Although this map is saturated for populations of European ancestry, further research is needed to achieve equivalent saturation in other ancestries.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

  • Schmutzler, Rita
  • Schmitz-Luhn, Bjoern
  • Borisch, Bettina
  • Devilee, Peter
  • Eccles, Diana M
  • Hall, Per
  • Balmaña Gelpí, Judith
Breast cancer; Evidence-generating care; Risk-adjusted prevention, Cáncer de mama; Atención generadora de evidencia; Prevención ajustada al riesgo, Càncer de mama; Atenció generadora d'evidències; Prevenció ajustada al risc, Background: Risk-adjusted cancer screening and prevention is a promising and continuously emerging option for improving cancer prevention. It is driven by increasing knowledge of risk factors and the ability to determine them for individual risk prediction. However, there is a knowledge gap between evidence of increased risk and evidence of the effectiveness and efficiency of clinical preventive interventions based on increased risk. This gap is, in particular, aggravated by the extensive availability of genetic risk factor diagnostics, since the question of appropriate preventive measures immediately arises when an increased risk is identified. However, collecting proof of effective preventive measures, ideally by prospective randomized preventive studies, typically requires very long periods of time, while the knowledge about an increased risk immediately creates a high demand for action. Summary: Therefore, we propose a risk-adjusted prevention concept that is based on the best current evidence making needed and appropriate preventive measures available, and which is constantly evaluated through outcome evaluation, and continuously improved based on these results. We further discuss the structural and procedural requirements as well as legal and socioeconomical aspects relevant for the implementation of this concept., The project was funded by the German Federal Ministry of Health (grant No. 2515FSB401 to Rita Schmutzler and Christiane Woopen) for supporting the international expert meetings, and a grant of the EU Horizon 2020 program, BRIDGES (grant No. 634935, PI Peter Devilee, WP5-PI Rita Schmutzler), for the compilation of the most recent findings of genetic risk prediction.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model

  • Mavaddat, Nasim
  • Ficorella, Lorenzo
  • Carver, Tim
  • Lee, Andrew
  • Cunningham, Alex P.
  • Pardo Muñoz, Monica
  • Balmaña Gelpí, Judith
  • Lush, Michael
Polygenic risk; Prediction; Breast cancer, Riesgo poligénico; Predicción; Cáncer de mama, Risc poligènic; Predicció; Càncer de mama, Background: The multifactorial risk prediction model BOADICEA enables identification of women at higher or lower risk of developing breast cancer. BOADICEA models genetic susceptibility in terms of the effects of rare variants in breast cancer susceptibility genes and a polygenic component, decomposed into an unmeasured and a measured component - the polygenic risk score (PRS). The current version was developed using a 313 SNP PRS. Here, we evaluated approaches to incorporating this PRS and alternative PRS in BOADICEA. Methods: The mean, SD, and proportion of the overall polygenic component explained by the PRS (α2) need to be estimated. α was estimated using logistic regression, where the age-specific log-OR is constrained to be a function of the age-dependent polygenic relative risk in BOADICEA; and using a retrospective likelihood (RL) approach that models, in addition, the unmeasured polygenic component. Results: Parameters were computed for 11 PRS, including 6 variations of the 313 SNP PRS used in clinical trials and implementation studies. The logistic regression approach underestimates α⁠, as compared with the RL estimates. The RL α estimates were very close to those obtained by assuming proportionality to the OR per 1 SD, with the constant of proportionality estimated using the 313 SNP PRS. Small variations in the SNPs included in the PRS can lead to large differences in the mean. Conclusions: BOADICEA can be readily adapted to different PRS in a manner that maintains consistency of the model., This work has been supported by grants from Cancer Research UK (PPRPGM-Nov20\100002); the European Union's Horizon 2020 Research and Innovation Programme under grant agreement numbers 633784 (B-CAST) and 634935 (BRIDGES); the PERSPECTIVE I&I project which is funded by the Government of Canada through Genome Canada (#13529) and the Canadian Institutes of Health Research (#155865), the Ministère de l’Économie et de l'Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund; and by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20014). BCAC is funded by the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and the PERSPECTIVE I&I project. Additional funding for BCAC is provided via the Confluence project which is funded with intramural funds from the NCI Intramural Research Program, NIH. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer Research UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l’Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. MT was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20014) and Cancer Research UK C22770/A31523 (International Alliance for Cancer Early Detection programme). The PRISMA study has been funded by Instituto de Salud Carlos III through the project " PI19/01195″ (Co-funded by European Regional Development Fund "A way to make Europe") and it received the institutional support of CERCA Program (Generalitat de Catalunya). The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.